false 2023 Q2 0000832101 12/31 http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent 0000832101 2023-01-01 2023-06-30 0000832101 2023-07-21 xbrli:shares 0000832101 2023-06-30 iso4217:USD 0000832101 2022-12-31 iso4217:USD xbrli:shares 0000832101 2023-04-01 2023-06-30 0000832101 2022-04-01 2022-06-30 0000832101 2022-01-01 2022-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000832101 us-gaap:RetainedEarningsMember 2022-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000832101 us-gaap:TreasuryStockCommonMember 2022-12-31 0000832101 us-gaap:ParentMember 2022-12-31 0000832101 us-gaap:NoncontrollingInterestMember 2022-12-31 0000832101 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000832101 us-gaap:ParentMember 2023-01-01 2023-03-31 0000832101 2023-01-01 2023-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-03-31 0000832101 us-gaap:RetainedEarningsMember 2023-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2023-03-31 0000832101 us-gaap:ParentMember 2023-03-31 0000832101 us-gaap:NoncontrollingInterestMember 2023-03-31 0000832101 2023-03-31 0000832101 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000832101 us-gaap:ParentMember 2023-04-01 2023-06-30 0000832101 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0000832101 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-06-30 0000832101 us-gaap:RetainedEarningsMember 2023-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000832101 us-gaap:TreasuryStockCommonMember 2023-06-30 0000832101 us-gaap:ParentMember 2023-06-30 0000832101 us-gaap:NoncontrollingInterestMember 2023-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000832101 us-gaap:RetainedEarningsMember 2021-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000832101 us-gaap:TreasuryStockCommonMember 2021-12-31 0000832101 us-gaap:ParentMember 2021-12-31 0000832101 us-gaap:NoncontrollingInterestMember 2021-12-31 0000832101 2021-12-31 0000832101 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000832101 us-gaap:ParentMember 2022-01-01 2022-03-31 0000832101 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000832101 2022-01-01 2022-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-03-31 0000832101 us-gaap:RetainedEarningsMember 2022-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0000832101 us-gaap:TreasuryStockCommonMember 2022-03-31 0000832101 us-gaap:ParentMember 2022-03-31 0000832101 us-gaap:NoncontrollingInterestMember 2022-03-31 0000832101 2022-03-31 0000832101 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000832101 us-gaap:ParentMember 2022-04-01 2022-06-30 0000832101 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-04-01 2022-06-30 0000832101 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-06-30 0000832101 us-gaap:RetainedEarningsMember 2022-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000832101 us-gaap:TreasuryStockCommonMember 2022-06-30 0000832101 us-gaap:ParentMember 2022-06-30 0000832101 us-gaap:NoncontrollingInterestMember 2022-06-30 0000832101 2022-06-30 0000832101 iex:FivePointOneThreePercentSeniorNotesMember us-gaap:SeniorNotesMember 2023-06-30 xbrli:pure 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2023-06-30 0000832101 iex:IridianSpectralTechnologiesMember 2023-05-19 2023-05-19 0000832101 iex:IridianSpectralTechnologiesMember 2023-04-25 0000832101 us-gaap:TradeNamesMember iex:IridianSpectralTechnologiesMember 2023-04-25 2023-04-25 0000832101 us-gaap:CustomerRelationshipsMember iex:IridianSpectralTechnologiesMember 2023-04-25 2023-04-25 0000832101 iex:IridianSpectralTechnologiesMember us-gaap:UnpatentedTechnologyMember 2023-04-25 2023-04-25 0000832101 iex:IridianSpectralTechnologiesMember 2023-04-25 2023-04-25 0000832101 iex:IridianSpectralTechnologiesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 iex:IridianSpectralTechnologiesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 iex:NexsightLLCMember 2022-02-28 0000832101 iex:NexsightLLCMember us-gaap:TradeNamesMember 2022-02-28 2022-02-28 0000832101 iex:NexsightLLCMember us-gaap:CustomerRelationshipsMember 2022-02-28 2022-02-28 0000832101 iex:NexsightLLCMember us-gaap:SoftwareDevelopmentMember 2022-02-28 2022-02-28 0000832101 iex:NexsightLLCMember 2022-02-28 2022-02-28 0000832101 iex:KZValveMember 2022-05-02 2022-05-02 0000832101 iex:KZValveMember 2022-05-02 0000832101 us-gaap:TradeNamesMember iex:KZValveMember 2022-05-02 2022-05-02 0000832101 us-gaap:CustomerRelationshipsMember iex:KZValveMember 2022-05-02 2022-05-02 0000832101 iex:KZValveMember us-gaap:UnpatentedTechnologyMember 2022-05-02 2022-05-02 0000832101 iex:MuonLLCMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember iex:CashOnHandMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2022-11-18 2022-11-18 0000832101 us-gaap:SecuredDebtMember iex:MuonLLCMember us-gaap:LineOfCreditMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:TradeNamesMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:CustomerRelationshipsMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:UnpatentedTechnologyMember 2022-11-18 2022-11-18 0000832101 iex:MuonLLCMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0000832101 iex:MuonLLCMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0000832101 iex:NexsightLLCMember us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0000832101 us-gaap:CostOfSalesMember iex:KZValveMember 2022-01-01 2022-06-30 0000832101 iex:ConvertiblePromissoryNoteMember 2022-01-01 2022-12-31 0000832101 iex:ConvertiblePromissoryNoteMember 2021-01-01 2021-12-31 0000832101 iex:ConvertiblePromissoryNoteMember 2023-01-01 2023-06-30 iex:segment 0000832101 iex:FluidAndMeteringTechnologiesMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:IntersegmentEliminationMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:IntersegmentEliminationMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:IntersegmentEliminationMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:IntersegmentEliminationMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:IntersegmentEliminationMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:IntersegmentEliminationMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:IntersegmentEliminationMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:IntersegmentEliminationMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2023-04-01 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2022-04-01 2022-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2023-04-01 2023-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2022-04-01 2022-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2023-01-01 2023-06-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2022-01-01 2022-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2023-04-01 2023-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2022-04-01 2022-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-06-30 0000832101 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-06-30 0000832101 us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2023-04-01 2023-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2022-12-31 0000832101 iex:HealthAndScienceTechnologiesMember 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember 2022-12-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2022-12-31 0000832101 us-gaap:CorporateNonSegmentMember 2023-06-30 0000832101 us-gaap:CorporateNonSegmentMember 2022-12-31 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:PumpsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:PumpsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:PumpsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:PumpsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:Water1Member us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:Water1Member us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:Water1Member us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:Water1Member us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:EnergyMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:EnergyMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:EnergyMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:EnergyMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:AgricultureMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:ValvesMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:ValvesMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:ValvesMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember iex:ValvesMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:PerformancePneumaticTechnologiesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:PerformancePneumaticTechnologiesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:PerformancePneumaticTechnologiesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:PerformancePneumaticTechnologiesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:SealingSolutionsMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:SealingSolutionsMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:SealingSolutionsMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:SealingSolutionsMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember iex:MicropumpMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember iex:MicropumpMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember iex:MicropumpMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember iex:MicropumpMember 2022-01-01 2022-06-30 0000832101 iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:DispensingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:DispensingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:DispensingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:DispensingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:BandItMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:BandItMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:BandItMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:BandItMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember country:US us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 country:US iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 country:US iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:EuropeMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 srt:EuropeMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:AsiaMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 srt:AsiaMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember country:US us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 country:US iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 country:US iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:EuropeMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 srt:EuropeMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:AsiaMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 srt:AsiaMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember country:US us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 country:US iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 country:US iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:EuropeMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 srt:EuropeMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:AsiaMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 srt:AsiaMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember country:US us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 country:US iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 country:US iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:EuropeMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 srt:EuropeMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 srt:EuropeMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember srt:AsiaMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 srt:AsiaMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 srt:AsiaMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:OtherGeographicalAreasMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0000832101 us-gaap:ProductConcentrationRiskMember us-gaap:TransferredAtPointInTimeMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-06-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-04-01 2022-06-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-01-01 2023-06-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2023-04-01 2023-06-30 0000832101 iex:BilledReceivablesMember 2023-06-30 0000832101 iex:BilledReceivablesMember 2022-12-31 0000832101 us-gaap:PatentsMember 2023-06-30 0000832101 us-gaap:PatentsMember 2022-12-31 0000832101 us-gaap:TradeNamesMember 2023-06-30 0000832101 us-gaap:TradeNamesMember 2022-12-31 0000832101 us-gaap:CustomerRelationshipsMember 2023-06-30 0000832101 us-gaap:CustomerRelationshipsMember 2022-12-31 0000832101 us-gaap:UnpatentedTechnologyMember 2023-06-30 0000832101 us-gaap:UnpatentedTechnologyMember 2022-12-31 0000832101 us-gaap:SoftwareDevelopmentMember 2023-06-30 0000832101 us-gaap:SoftwareDevelopmentMember 2022-12-31 0000832101 iex:BanjoTradeNameMember 2023-06-30 0000832101 iex:BanjoTradeNameMember 2022-12-31 0000832101 iex:AkronBrasstradenameMember 2023-06-30 0000832101 iex:AkronBrasstradenameMember 2022-12-31 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2022-12-31 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2023-06-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2022-12-31 0000832101 iex:FivePointOneThreePercentSeniorNotesMember us-gaap:SeniorNotesMember 2022-12-31 0000832101 iex:ThreePointZeroPercentSeniorNotesDueMay2030Member us-gaap:SeniorNotesMember 2023-06-30 0000832101 iex:ThreePointZeroPercentSeniorNotesDueMay2030Member us-gaap:SeniorNotesMember 2022-12-31 0000832101 us-gaap:SeniorNotesMember iex:TwoPointSixTwoFivePercentSeniorNotesDue2031Member 2023-06-30 0000832101 us-gaap:SeniorNotesMember iex:TwoPointSixTwoFivePercentSeniorNotesDue2031Member 2022-12-31 0000832101 us-gaap:RevolvingCreditFacilityMember 2023-06-30 0000832101 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2023-06-30 0000832101 us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2022-12-31 0000832101 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2023-06-30 0000832101 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2022-12-31 0000832101 iex:FivePointOneThreePercentSeniorNotesMember us-gaap:SeniorNotesMember 2023-06-13 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2023-06-13 0000832101 iex:FivePointOneThreePercentSeniorNotesMember srt:MinimumMember us-gaap:SeniorNotesMember 2023-06-13 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000832101 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0000832101 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000832101 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000832101 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0000832101 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000832101 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 iex:option 0000832101 us-gaap:BuildingMember 2023-06-30 0000832101 us-gaap:BuildingMember 2022-12-31 0000832101 us-gaap:EquipmentMember 2023-06-30 0000832101 us-gaap:EquipmentMember 2022-12-31 0000832101 iex:BuildingAndEquipmentMember 2023-06-30 0000832101 iex:BuildingAndEquipmentMember 2022-12-31 0000832101 us-gaap:VehiclesMember 2023-06-30 0000832101 us-gaap:VehiclesMember 2022-12-31 0000832101 us-gaap:EmployeeSeveranceMember iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:CorporateNonSegmentMember 2023-04-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember us-gaap:CorporateNonSegmentMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember 2023-04-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:CorporateNonSegmentMember 2023-01-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember us-gaap:CorporateNonSegmentMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-06-30 0000832101 us-gaap:FacilityClosingMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember 2022-04-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FluidAndMeteringTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 iex:FluidAndMeteringTechnologiesMember us-gaap:FacilityClosingMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember iex:HealthAndScienceTechnologiesMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0000832101 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-06-30 0000832101 us-gaap:FacilityClosingMember 2022-01-01 2022-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-04-01 2022-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-06-30 0000832101 2020-03-17 2020-03-17 0000832101 2015-12-01 2015-12-01 0000832101 us-gaap:SubsequentEventMember 2023-07-01 2023-07-27 0000832101 2022-07-01 2022-07-31 0000832101 iex:EmployeesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000832101 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000832101 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0000832101 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000832101 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0000832101 iex:AcceleratedStockRetireeEligibilityMember us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 iex:AcceleratedStockRetireeEligibilityMember us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 us-gaap:EmployeeStockOptionMember 2022-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2023-06-30 0000832101 iex:EmployeesandNonemployeeDirectorsMember us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember 2022-12-31 0000832101 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember 2023-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0000832101 us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0000832101 us-gaap:RestrictedStockMember 2022-04-01 2022-06-30 0000832101 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0000832101 iex:CashsettledRestrictedStockMember 2023-01-01 2023-06-30 0000832101 iex:CashsettledRestrictedStockMember 2022-12-31 0000832101 iex:CashsettledRestrictedStockMember 2023-06-30 0000832101 us-gaap:CostOfSalesMember iex:CashsettledRestrictedStockMember 2023-04-01 2023-06-30 0000832101 us-gaap:CostOfSalesMember iex:CashsettledRestrictedStockMember 2022-04-01 2022-06-30 0000832101 us-gaap:CostOfSalesMember iex:CashsettledRestrictedStockMember 2023-01-01 2023-06-30 0000832101 us-gaap:CostOfSalesMember iex:CashsettledRestrictedStockMember 2022-01-01 2022-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0000832101 iex:CashsettledRestrictedStockMember 2023-04-01 2023-06-30 0000832101 iex:CashsettledRestrictedStockMember 2022-04-01 2022-06-30 0000832101 iex:CashsettledRestrictedStockMember 2022-01-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember 2022-01-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember 2022-12-31 0000832101 us-gaap:PerformanceSharesMember 2023-06-30 0000832101 us-gaap:PerformanceSharesMember 2023-01-31 2023-01-31 0000832101 us-gaap:PerformanceSharesMember 2023-02-01 2023-02-28 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2022-04-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember 2023-04-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember 2022-04-01 2022-06-30 0000832101 us-gaap:PerformanceSharesMember iex:AcceleratedStockRetireeEligibilityMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0000832101 us-gaap:PerformanceSharesMember iex:AcceleratedStockRetireeEligibilityMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-04-01 2023-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-04-01 2023-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-04-01 2022-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-04-01 2022-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-06-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-06-30 0000832101 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-04-01 2023-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-04-01 2022-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-06-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember 2023-06-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-06-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
Form 10-Q

☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the quarterly period ended | June 30, 2023

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the transition period from | to

Commission File Number: 1-10235
IDEX CORPORATION
(Exact name of registrant as specified in its charter)

| Delaware |  | 36-3555336
| (State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
| 3100 Sanders Road, | Suite 301, | Northbrook, | Illinois |  | 60062
| (Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (847) 498-7070
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $.01 per share |  | IEX |  | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☑ |  | Accelerated filer ☐ |  | Non-accelerated filer ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |  |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
Number of shares of common stock of IDEX Corporation outstanding as of July 21, 2023: 75,601,661.

Table of Contents
TABLE OF CONTENTS

Part I. Financial Information |
Item 1. | Financial Statements | 1
| Condensed Consolidated Balance Sheets | 1
| Condensed Consolidated Statements of Income | 2
| Condensed Consolidated Statements of Comprehensive Income | 3
| Condensed Consolidated Statements of Equity | 4
| Condensed Consolidated Statements of Cash Flows | 5
| Notes to Condensed Consolidated Financial Statements | 6
| Note 1. Basis of Presentation and Significant Accounting Policies | 6
| Note 2. Acquisitions | 6
| Note 3. Collaborative Investments | 10
| Note 4. Business Segments | 10
| Note 5. Revenue | 13
| Note 6. Earnings Per Common Share | 15
| Note 7. Balance Sheet Components | 17
| Note 8. Goodwill and Intangible Assets | 17
| Note 9. Borrowings | 19
| Note 10. Fair Value Measurements | 20
| Note 11. Leases | 21
| Note 12. Restructuring Expenses and Asset Impairments | 22
| Note 13. Other Comprehensive Income (Loss) | 24
| Note 14. Share Repurchases | 24
| Note 15. Share-Based Compensation | 25
| Note 16. Retirement Benefits | 29
| Note 17. Legal Proceedings | 30
| Note 18. Income Taxes | 30
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 31
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 45
Item 4. | Controls and Procedures | 45
Part II. Other Information |
Item 1. | Legal Proceedings | 46
Item 1A. | Risk Factors | 46
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 46
Item 5. | Other Information | 46
Item 6. | Exhibits | 47
Signatures | 48

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in millions, except per share amounts)
(unaudited)

| June 30, 2023 |  | December 31, 2022
ASSETS |  |  |
Current assets |  |  |
Cash and cash equivalents | $ | 457.0 |  |  | $ | 430.2 |
Receivables, less allowance for credit losses of $7.0 and $8.0, respectively | 455.2 |  |  | 442.8 |
Inventories | 482.5 |  |  | 470.9 |
Other current assets | 93.2 |  |  | 55.4 |
Total current assets | 1,487.9 |  |  | 1,399.3 |
Property, plant and equipment, net of accumulated depreciation of $538.8 and $516.7, respectively | 421.6 |  |  | 382.1 |
Goodwill | 2,714.4 |  |  | 2,638.1 |
Intangible assets - net | 957.3 |  |  | 947.8 |
Other noncurrent assets | 138.7 |  |  | 144.6 |
Total assets | $ | 5,719.9 |  |  | $ | 5,511.9 |
LIABILITIES AND EQUITY |  |  |
Current liabilities |  |  |
Trade accounts payable | $ | 189.7 |  |  | $ | 208.9 |
Accrued expenses | 247.9 |  |  | 289.1 |
Short-term borrowings | 0.5 |  |  | — |
Dividends payable | 48.5 |  |  | 45.6 |
Total current liabilities | 486.6 |  |  | 543.6 |
Long-term borrowings | 1,471.5 |  |  | 1,468.7 |
Deferred income taxes | 286.1 |  |  | 264.2 |
Other noncurrent liabilities | 196.8 |  |  | 195.8 |
Total liabilities | 2,441.0 |  |  | 2,472.3 |
Commitments and contingencies |  |  |
Shareholders’ equity |  |  |
Preferred stock: |  |  |
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None | — |  |  | — |
Common stock: |  |  |
Authorized: 150,000,000 shares, $.01 per share par value |  |  |
Issued: 90,073,221 shares at June 30, 2023 and 90,064,988 shares at December 31, 2022 | 0.9 |  |  | 0.9 |
Additional paid-in capital | 834.2 |  |  | 817.2 |
Retained earnings | 3,713.4 |  |  | 3,531.7 |
Treasury stock at cost: 14,367,209 shares at June 30, 2023 and 14,451,032 shares at December 31, 2022 | (1,182.0) |  |  | (1,184.3) |
Accumulated other comprehensive loss | (87.8) |  |  | (126.2) |
Total shareholders’ equity | 3,278.7 |  |  | 3,039.3 |
Noncontrolling interest | 0.2 |  |  | 0.3 |
Total equity | 3,278.9 |  |  | 3,039.6 |
Total liabilities and equity | $ | 5,719.9 |  |  | $ | 5,511.9 |

See Notes to Condensed Consolidated Financial Statements
1

Table of Contents
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
(unaudited)

| Three Months Ended June 30, |  | Six Months Ended June 30, |  |
| 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  |
Net sales | $ | 846.2 |  |  | $ | 796.1 |  |  | $ | 1,691.6 |  |  | $ | 1,547.2 |  |  |  |  |
Cost of sales | 468.2 |  |  | 439.2 |  |  | 931.1 |  |  | 847.8 |  |  |  |  |
Gross profit | 378.0 |  |  | 356.9 |  |  | 760.5 |  |  | 699.4 |  |  |  |  |
Selling, general and administrative expenses | 174.3 |  |  | 167.5 |  |  | 364.0 |  |  | 321.8 |  |  |  |  |
Restructuring expenses and asset impairments | 3.6 |  |  | 2.8 |  |  | 4.1 |  |  | 3.4 |  |  |  |  |
Operating income | 200.1 |  |  | 186.6 |  |  | 392.4 |  |  | 374.2 |  |  |  |  |
Other expense (income) - net | 8.3 |  |  | — |  |  | 7.7 |  |  | (2.3) |  |  |  |  |
Interest expense | 13.3 |  |  | 9.5 |  |  | 26.4 |  |  | 19.0 |  |  |  |  |
Income before income taxes | 178.5 |  |  | 177.1 |  |  | 358.3 |  |  | 357.5 |  |  |  |  |
Provision for income taxes | 40.0 |  |  | 39.0 |  |  | 80.0 |  |  | 79.5 |  |  |  |  |
Net income | 138.5 |  |  | 138.1 |  |  | 278.3 |  |  | 278.0 |  |  |  |  |
Net loss attributable to noncontrolling interest | 0.1 |  |  | 0.1 |  |  | 0.1 |  |  | 0.2 |  |  |  |  |
Net income attributable to IDEX | $ | 138.6 |  |  | $ | 138.2 |  |  | $ | 278.4 |  |  | $ | 278.2 |  |  |  |  |
Earnings per common share: |  |  |  |  |  |  |  |  |  |  |
Basic earnings per common share attributable to IDEX | $ | 1.83 |  |  | $ | 1.82 |  |  | $ | 3.68 |  |  | $ | 3.66 |  |  |  |  |
Diluted earnings per common share attributable to IDEX | $ | 1.82 |  |  | $ | 1.81 |  |  | $ | 3.66 |  |  | $ | 3.65 |  |  |  |  |
Share data: |  |  |  |  |  |  |  |  |  |  |
Basic weighted average common shares outstanding | 75.6 |  |  | 75.8 |  |  | 75.6 |  |  | 76.0 |  |  |  |  |
Diluted weighted average common shares outstanding | 75.9 |  |  | 76.1 |  |  | 75.9 |  |  | 76.2 |  |  |  |  |

See Notes to Condensed Consolidated Financial Statements
2

Table of Contents
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(unaudited)

| Three Months Ended June 30, |  | Six Months Ended June 30, |  |
| 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  |
Net income | $ | 138.5 |  |  | $ | 138.1 |  |  | $ | 278.3 |  |  | $ | 278.0 |  |  |  |  |
Other comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |
Pension and other postretirement adjustments, net of tax | (0.9) |  |  | 0.6 |  |  | (0.5) |  |  | 1.2 |  |  |  |  |
Cumulative translation adjustment | 2.3 |  |  | (81.9) |  |  | 38.9 |  |  | (101.4) |  |  |  |  |
Other comprehensive income (loss) | 1.4 |  |  | (81.3) |  |  | 38.4 |  |  | (100.2) |  |  |  |  |
Comprehensive income | 139.9 |  |  | 56.8 |  |  | 316.7 |  |  | 177.8 |  |  |  |  |
Comprehensive loss attributable to noncontrolling interest | 0.1 |  |  | 0.1 |  |  | 0.1 |  |  | 0.2 |  |  |  |  |
Comprehensive income attributable to IDEX | $ | 140.0 |  |  | $ | 56.9 |  |  | $ | 316.8 |  |  | $ | 178.0 |  |  |  |  |

See Notes to Condensed Consolidated Financial Statements
3

Table of Contents
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Dollars in millions)
(unaudited)

|  |  |  |  | Accumulated Other Comprehensive Loss |  |  |  |  |  |  |  |
| Common Stock and Additional Paid-In Capital |  | Retained Earnings |  | Cumulative Translation Adjustment |  | Retirement Benefits Adjustment |  | Treasury Stock |  | Total Shareholders’ Equity |  | Noncontrolling Interest |  | Total Equity
Balance, December 31, 2022 | $ | 818.1 |  |  | $ | 3,531.7 |  |  | $ | (137.1) |  |  | $ | 10.9 |  |  | $ | (1,184.3) |  |  | $ | 3,039.3 |  |  | $ | 0.3 |  |  | $ | 3,039.6 |
Net income | — |  |  | 139.8 |  |  | — |  |  | — |  |  | — |  |  | 139.8 |  |  | — |  |  | 139.8 |
Cumulative translation adjustment | — |  |  | — |  |  | 36.6 |  |  | — |  |  | — |  |  | 36.6 |  |  | — |  |  | 36.6 |
Net change in retirement obligations (net of tax of $0.2) | — |  |  | — |  |  | — |  |  | 0.4 |  |  | — |  |  | 0.4 |  |  | — |  |  | 0.4 |
Issuance of 84,666 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $1.8) | — |  |  | — |  |  | — |  |  | — |  |  | 4.7 |  |  | 4.7 |  |  | — |  |  | 4.7 |
Shares surrendered for tax withholding | — |  |  | — |  |  | — |  |  | — |  |  | (4.4) |  |  | (4.4) |  |  | — |  |  | (4.4) |
Share-based compensation | 12.8 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 12.8 |  |  | — |  |  | 12.8 |
Balance, March 31, 2023 | $ | 830.9 |  |  | $ | 3,671.5 |  |  | $ | (100.5) |  |  | $ | 11.3 |  |  | $ | (1,184.0) |  |  | $ | 3,229.2 |  |  | $ | 0.3 |  |  | $ | 3,229.5 |
Net income (loss) | — |  |  | 138.6 |  |  | — |  |  | — |  |  | — |  |  | 138.6 |  |  | (0.1) |  |  | 138.5 |
Cumulative translation adjustment | — |  |  | — |  |  | 2.3 |  |  | — |  |  | — |  |  | 2.3 |  |  | — |  |  | 2.3 |
Net change in retirement obligations (net of tax of $(0.4)) | — |  |  | — |  |  | — |  |  | (0.9) |  |  | — |  |  | (0.9) |  |  | — |  |  | (0.9) |
Issuance of 26,763 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $0.3) | — |  |  | — |  |  | — |  |  | — |  |  | 3.3 |  |  | 3.3 |  |  | — |  |  | 3.3 |
Repurchase of 5,400 shares of common stock | — |  |  | — |  |  | — |  |  | — |  |  | (1.1) |  |  | (1.1) |  |  | — |  |  | (1.1) |
Shares surrendered for tax withholding | — |  |  | — |  |  | — |  |  | — |  |  | (0.2) |  |  | (0.2) |  |  | — |  |  | (0.2) |
Share-based compensation | 4.2 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4.2 |  |  | — |  |  | 4.2 |
Cash dividends declared - $1.28 per common share outstanding | — |  |  | (96.7) |  |  | — |  |  | — |  |  | — |  |  | (96.7) |  |  | — |  |  | (96.7) |
Balance, June 30, 2023 | $ | 835.1 |  |  | $ | 3,713.4 |  |  | $ | (98.2) |  |  | $ | 10.4 |  |  | $ | (1,182.0) |  |  | $ | 3,278.7 |  |  | $ | 0.2 |  |  | $ | 3,278.9 |

|  |  |  |  | Accumulated Other Comprehensive Loss |  |  |  |  |  |  |  |
| Common Stock and Additional Paid-In Capital |  | Retained Earnings |  | Cumulative Translation Adjustment |  | Retirement Benefits Adjustment |  |  |  | Treasury Stock |  | Total Shareholders’ Equity |  | Noncontrolling Interest |  | Total Equity
Balance, December 31, 2021 | $ | 796.5 |  |  | $ | 3,126.5 |  |  | $ | (62.2) |  |  | $ | (7.4) |  |  |  |  | $ | (1,050.3) |  |  | $ | 2,803.1 |  |  | $ | — |  |  | $ | 2,803.1 |
Net income (loss) | — |  |  | 140.0 |  |  | — |  |  | — |  |  |  |  | — |  |  | 140.0 |  |  | (0.1) |  |  | 139.9 |
Cumulative translation adjustment | — |  |  | — |  |  | (19.5) |  |  | — |  |  |  |  | — |  |  | (19.5) |  |  | — |  |  | (19.5) |
Net change in retirement obligations (net of tax of $0.2) | — |  |  | — |  |  | — |  |  | 0.6 |  |  |  |  | — |  |  | 0.6 |  |  | — |  |  | 0.6 |
Issuance of 73,755 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $1.7) | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 1.4 |  |  | 1.4 |  |  | — |  |  | 1.4 |
Repurchase of 147,500 shares of common stock | — |  |  | — |  |  | — |  |  | — |  |  |  |  | (28.3) |  |  | (28.3) |  |  | — |  |  | (28.3) |
Shares surrendered for tax withholding | — |  |  | — |  |  | — |  |  | — |  |  |  |  | (4.9) |  |  | (4.9) |  |  | — |  |  | (4.9) |
Share-based compensation | 6.6 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 6.6 |  |  | — |  |  | 6.6 |
Balance, March 31, 2022 | $ | 803.1 |  |  | $ | 3,266.5 |  |  | $ | (81.7) |  |  | $ | (6.8) |  |  |  |  | $ | (1,082.1) |  |  | $ | 2,899.0 |  |  | $ | (0.1) |  |  | $ | 2,898.9 |
Net income (loss) | — |  |  | 138.2 |  |  | — |  |  | — |  |  |  |  | — |  |  | 138.2 |  |  | (0.1) |  |  | 138.1 |
Cumulative translation adjustment | — |  |  | — |  |  | (81.9) |  |  | — |  |  |  |  | — |  |  | (81.9) |  |  | — |  |  | (81.9) |
Net change in retirement obligations (net of tax of $0.5) | — |  |  | — |  |  | — |  |  | 0.6 |  |  |  |  | — |  |  | 0.6 |  |  | — |  |  | 0.6 |
Issuance of 42,408 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $0.4) | — |  |  | — |  |  | — |  |  | — |  |  |  |  | 3.8 |  |  | 3.8 |  |  | — |  |  | 3.8 |
Repurchase of 474,690 shares of common stock | — |  |  | — |  |  | — |  |  | — |  |  |  |  | (87.5) |  |  | (87.5) |  |  | — |  |  | (87.5) |
Share-based compensation | 6.9 |  |  | — |  |  | — |  |  | — |  |  |  |  | — |  |  | 6.9 |  |  | — |  |  | 6.9 |
Cash dividends declared - $1.20 per common share outstanding | — |  |  | (90.9) |  |  | — |  |  | — |  |  |  |  | — |  |  | (90.9) |  |  | — |  |  | (90.9) |
Balance, June 30, 2022 | $ | 810.0 |  |  | $ | 3,313.8 |  |  | $ | (163.6) |  |  | $ | (6.2) |  |  |  |  | $ | (1,165.8) |  |  | $ | 2,788.2 |  |  | $ | (0.2) |  |  | $ | 2,788.0 |

See Notes to Condensed Consolidated Financial Statements
4

Table of Contents
IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(unaudited)

| Six Months Ended June 30,
| 2023 |  | 2022
Cash flows from operating activities |  |  |
Net income | $ | 278.3 |  |  | $ | 278.0 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
Gains on sales of assets | (0.2) |  |  | (2.6) |
Asset impairments | 0.5 |  |  | 0.2 |
Credit loss on note receivable from collaborative partner | 7.7 |  |  | — |
Depreciation | 27.2 |  |  | 24.7 |
Amortization of intangible assets | 46.8 |  |  | 32.2 |
Amortization of debt issuance expenses | 0.8 |  |  | 0.8 |
Share-based compensation expense | 17.0 |  |  | 13.5 |
Deferred income taxes | — |  |  | (0.2) |
Changes in (net of the effect from acquisitions and foreign exchange): |  |  |
Receivables | (5.8) |  |  | (68.7) |
Inventories | (2.0) |  |  | (84.5) |
Other current assets | (18.6) |  |  | (17.8) |
Trade accounts payable | (17.9) |  |  | 36.2 |
Deferred revenue | 4.2 |  |  | 1.3 |
Accrued expenses | (52.5) |  |  | (22.5) |
Other - net | 3.6 |  |  | 1.4 |
Net cash flows provided by operating activities | 289.1 |  |  | 192.0 |
Cash flows from investing activities |  |  |
Purchases of property, plant and equipment | (48.2) |  |  | (31.7) |
Acquisition of businesses, net of cash acquired | (110.3) |  |  | (234.9) |
Proceeds from disposal of fixed assets | 1.3 |  |  | 6.6 |
Purchases of marketable securities | (19.1) |  |  | — |
Other - net | (0.3) |  |  | (0.1) |
Net cash flows used in investing activities | (176.6) |  |  | (260.1) |
Cash flows from financing activities |  |  |
Proceeds from issuance of 5.13% Senior Notes | 100.0 |  |  | — |
Payment of 3.20% Senior Notes | (100.0) |  |  | — |
Dividends paid | (93.9) |  |  | (86.9) |
Proceeds from stock option exercises | 8.0 |  |  | 5.2 |
Repurchases of common stock | (1.0) |  |  | (110.4) |
Shares surrendered for tax withholding | (4.6) |  |  | (4.9) |
Other - net | (0.5) |  |  | (0.1) |
Net cash flows used in financing activities | (92.0) |  |  | (197.1) |
Effect of exchange rate changes on cash and cash equivalents | 6.3 |  |  | (32.4) |
Net increase (decrease) in cash and cash equivalents | 26.8 |  |  | (297.6) |
Cash and cash equivalents at beginning of year | 430.2 |  |  | 855.4 |
Cash and cash equivalents at end of period | $ | 457.0 |  |  | $ | 557.8 |
Supplemental cash flow information |  |  |
Cash paid for: |  |  |
Interest | $ | 25.1 |  |  | $ | 18.5 |
Income taxes | 102.9 |  |  | 86.9 |

See Notes to Condensed Consolidated Financial Statements
5

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
1. Basis of Presentation and Significant Accounting Policies
The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the entire year.
The Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Recently Adopted Accounting Standards
In October 2021, the Financial Accounting Standards Board issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which adds contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with revenue recognition guidance. The Company adopted this standard on a prospective basis for the annual and interim periods beginning January 1, 2023. The adoption of this standard did not have a material impact on the Company’s Condensed Consolidated Financial Statements.
2. Acquisitions
All of the Company’s acquisitions of businesses have been accounted for under Accounting Standards Codification (“ASC”) 805, Business Combinations. Accordingly, the assets and liabilities of the acquired companies, after adjustments to reflect the fair values assigned to the assets and liabilities, have been included in the Company’s Condensed Consolidated Financial Statements from their respective dates of acquisition. The results of operations of Nexsight, LLC and its businesses Envirosight, WinCan, MyTana and Pipeline Renewal Technologies (“Nexsight”) (acquired February 28, 2022), KZ CO. (“KZValve”) (acquired May 2, 2022), Muon B.V. and its subsidiaries (“Muon Group”) (acquired November 18, 2022) and Iridian Spectral Technologies ("Iridian") (acquired May 19, 2023) have been included in the Company’s Condensed Consolidated Financial Statements since the respective dates of acquisition. Supplemental pro forma information has not been provided as the acquisitions did not have a material impact on the Company’s Condensed Consolidated Financial Statements individually or in the aggregate.
2023 Acquisitions
Iridian
On May 19, 2023, the Company acquired Iridian in a stock acquisition. Iridian is a global leader in designing and manufacturing thin-film, multi-layer optical filters serving the laser communications, telecommunications and life sciences markets and expands the Company’s array of optical technology offerings. Headquartered in Ottawa, Ontario, Canada, Iridian operates in the Company’s Scientific Fluidics & Optics reporting unit within the Health & Science Technologies (“HST”) segment. Iridian was acquired for cash consideration of $110.3 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $53.6 million and $45.6 million, respectively. The goodwill is not deductible for tax purposes.
6

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The Company made a preliminary allocation of the purchase price for the Iridian acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information, primarily related to the valuations of these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.
The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

| Total
Current assets, net of cash acquired | $ | 10.6 |
Property, plant and equipment | 19.9 |
Goodwill | 53.6 |
Intangible assets | 45.6 |
Other noncurrent assets | 5.4 |
Total assets acquired | 135.1 |
Current liabilities | (1.2) |
Deferred income taxes | (18.7) |
Other noncurrent liabilities | (4.9) |
Net assets acquired | $ | 110.3 |

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.
The acquired intangible assets and weighted average amortization periods are as follows:

| Total |  | Weighted Average Life
Trade names | $ | 5.2 |  |  | 15
Customer relationships | 29.3 |  |  | 12
Unpatented technology | 11.1 |  |  | 11
Acquired intangible assets | $ | 45.6 |  |  |

The Company incurred $2.5 million and $3.6 million of acquisition-related costs during the three and six months ended June 30, 2023, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed transactions, pending transactions and potential transactions, including transactions that ultimately were not completed.
2022 Acquisitions
Nexsight
On February 28, 2022, the Company acquired Nexsight in a partial stock and asset acquisition. Nexsight complements and creates synergies with the Company’s existing iPEK and ADS business units that design and create sewer crawlers, inspection and monitoring systems and software applications that allow teams to identify, anticipate and correct wastewater system issues remotely. Headquartered in Randolph, New Jersey, Nexsight operates in the Company’s Water reporting unit within the Fluid & Metering Technologies (“FMT”) segment. Nexsight was acquired for cash consideration of $112.5 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $54.7 million and $49.8 million, respectively. The goodwill is partially deductible for tax purposes.
7

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
The Company finalized the allocation of the purchase price for the Nexsight acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.
The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

| Total
Current assets, net of cash acquired | $ | 16.6 |
Property, plant and equipment | 2.0 |
Goodwill | 54.7 |
Intangible assets | 49.8 |
Other noncurrent assets | 4.3 |
Total assets acquired | 127.4 |
Current liabilities | (9.2) |
Deferred income taxes | (1.9) |
Other noncurrent liabilities | (3.8) |
Net assets acquired | $ | 112.5 |

Acquired intangible assets consist of trade names, customer relationships and software. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.
The acquired intangible assets and weighted average amortization periods are as follows:

| Total |  | Weighted Average Life
Trade names | $ | 13.5 |  |  | 15
Customer relationships | 31.5 |  |  | 10
Software | 4.8 |  |  | 5
Acquired intangible assets | $ | 49.8 |  |  |

KZValve
On May 2, 2022, the Company acquired KZValve in an asset acquisition. KZValve is a leading manufacturer of electric valves and controllers used primarily in agricultural applications. KZValve augments and expands IDEX’s agricultural portfolio, complementing Banjo’s current fluid management solutions for these applications. Headquartered in Greenwood, Nebraska, KZValve operates in the Company’s Agriculture reporting unit within the FMT segment. KZValve was acquired for cash consideration of $120.1 million. The entire purchase was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $56.4 million and $52.0 million, respectively. The goodwill is deductible for tax purposes.
The Company finalized the allocation of the purchase price for the KZValve acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.
The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
8

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

| Total
Current assets, net of cash acquired | $ | 9.7 |
Property, plant and equipment | 1.8 |
Goodwill | 56.4 |
Intangible assets | 52.0 |
Deferred income taxes | 0.2 |
Other noncurrent assets | 1.0 |
Total assets acquired | 121.1 |
Current liabilities | (1.0) |
Net assets acquired | $ | 120.1 |

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.
The acquired intangible assets and weighted average amortization periods are as follows:

| Total |  | Weighted Average Life
Trade names | $ | 7.5 |  |  | 15
Customer relationships | 36.0 |  |  | 13
Unpatented technology | 8.5 |  |  | 10
Acquired intangible assets | $ | 52.0 |  |  |

Muon Group
On November 18, 2022, the Company acquired the stock of Muon Group. Muon Group manufactures highly precise flowpaths in a variety of materials that enable the movement of various liquids and gases in critical applications for medical, semiconductor, food processing, digital printing and filtration technologies. Muon Group maintains operations in Hapert, the Netherlands; Eerbeek, the Netherlands; Wijchen, the Netherlands; Dorset, United Kingdom and Pune, India and operates in the Company’s Scientific Fluidics & Optics reporting unit within the HST segment. Muon Group was acquired for cash consideration of $713.0 million. The purchase price was funded with $342.6 million of cash on hand, $170.4 million of proceeds from the Company's Revolving Credit Facility and $200.0 million of proceeds from the Company's Term Facility. Goodwill and intangible assets recognized as part of this transaction were $393.0 million and $319.1 million, respectively. The goodwill is not deductible for tax purposes.
The Company made a preliminary allocation of the purchase price for the Muon Group acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information, primarily related to the valuations of these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.
The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
9

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

| Total
Current assets, net of cash acquired | $ | 52.8 |
Property, plant and equipment | 59.1 |
Goodwill | 393.0 |
Intangible assets | 319.1 |
Other noncurrent assets | 9.6 |
Total assets acquired | 833.6 |
Current liabilities | (25.8) |
Deferred income taxes | (83.9) |
Other noncurrent liabilities | (10.9) |
Net assets acquired | $ | 713.0 |

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.
The acquired intangible assets and weighted average amortization periods are as follows:

| Total |  | Weighted Average Life
Trade names | $ | 38.3 |  |  | 15
Customer relationships | 212.4 |  |  | 13
Unpatented technology | 68.4 |  |  | 11
Acquired intangible assets | $ | 319.1 |  |  |

The Company incurred $1.7 million and $2.6 million of acquisition-related costs during the three and six months ended June 30, 2022, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed transactions, pending transactions and potential transactions, including transactions that ultimately were not completed. The Company also recorded $0.1 million and $0.3 million of fair value inventory step-up charges associated with the completed 2022 acquisitions of Nexsight and KZValve, respectively, in Cost of sales during the three and six months ended June 30, 2022.
3. Collaborative Investments
During 2021 and 2022, a subsidiary of IDEX funded a total of $7.2 million in promissory notes as an investment in a start-up company that provides communication technology to improve individual performance and team coordination for firefighters’ responses, which aligns with our FSDP segment’s strategic plan. On a quarterly basis, the Company evaluates whether an allowance for credit losses is required for these promissory notes and measures the allowance using the current expected credit loss model. While the Company continues to retain certain convertible equity rights as well as a secured interest in the intellectual property of the start-up company, during the second quarter of 2023, IDEX concluded it would pause additional funding for the start-up. As a result of the Company’s analysis of the recoverability of its investment during the second quarter, IDEX determined that its investment may no longer be recoverable. As a result, IDEX recorded a credit loss of $7.7 million in Other expense (income) - net in the Condensed Consolidated Statements of Income and a reserve in Other noncurrent assets on the Condensed Consolidated Balance Sheets for the full amount of the principal and accrued interest outstanding at June 30, 2023.
4. Business Segments
IDEX has three reportable business segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”).
The FMT segment designs, produces and distributes positive displacement pumps, valves, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the
10

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
food, chemical, general industrial, water and wastewater, agriculture and energy industries. FMT application-specific pump and metering solutions serve a diverse range of end markets, including industrial infrastructure (fossil fuels, refined and alternative fuels and water and wastewater), energy, chemical processing, agriculture, food and beverage, semiconductor, pulp and paper, automotive/transportation, plastics and resins, electronics and electrical, construction and mining, pharmaceutical and biopharmaceutical, machinery and numerous other specialty niche markets.
The HST segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems, micro-precision components, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, laboratory and commercial equipment, precision photonic solutions and precision gear and peristaltic pump technologies. HST serves a variety of end markets, including food and beverage, life sciences, analytical instruments, pharmaceutical and biopharmaceutical, industrial, semiconductor, digital printing, automotive/transportation, medical/dental, energy, cosmetics, marine, chemical, wastewater and water treatment, research and aerospace/defense markets.
The FSDP segment designs, produces and distributes firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications in the automotive, energy and industrial markets and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses in the paint and industrial markets around the world.
Information on the Company’s business segments is presented below based on the nature of the products and services offered. The Company uses Adjusted EBITDA as its principal measure of segment performance. Intersegment sales are contracted with terms equivalent to those of an arm’s-length transaction.
11

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Net sales |  |  |  |  |  |  |
Fluid & Metering Technologies |  |  |  |  |  |  |
External customers | $ | 324.1 |  |  | $ | 299.5 |  |  | $ | 645.2 |  |  | $ | 571.4 |
Intersegment sales | 1.0 |  |  | 0.4 |  |  | 1.7 |  |  | 0.5 |
Total segment sales | 325.1 |  |  | 299.9 |  |  | 646.9 |  |  | 571.9 |
Health & Science Technologies |  |  |  |  |  |  |
External customers | 338.4 |  |  | 325.4 |  |  | 688.7 |  |  | 640.0 |
Intersegment sales | 1.1 |  |  | 0.6 |  |  | 1.8 |  |  | 1.2 |
Total segment sales | 339.5 |  |  | 326.0 |  |  | 690.5 |  |  | 641.2 |
Fire & Safety/Diversified Products |  |  |  |  |  |  |
External customers | 183.7 |  |  | 171.2 |  |  | 357.7 |  |  | 335.8 |
Intersegment sales | 1.1 |  |  | — |  |  | 1.5 |  |  | 0.1 |
Total segment sales | 184.8 |  |  | 171.2 |  |  | 359.2 |  |  | 335.9 |
Intersegment eliminations | (3.2) |  |  | (1.0) |  |  | (5.0) |  |  | (1.8) |
Net sales | $ | 846.2 |  |  | $ | 796.1 |  |  | $ | 1,691.6 |  |  | $ | 1,547.2 |
ADJUSTED EBITDA |  |  |  |  |  |  |
Fluid & Metering Technologies | $ | 114.1 |  |  | $ | 95.0 |  |  | $ | 220.3 |  |  | $ | 183.4 |
Health & Science Technologies | 93.7 |  |  | 103.6 |  |  | 194.4 |  |  | 203.4 |
Fire & Safety/Diversified Products | 54.5 |  |  | 45.1 |  |  | 104.2 |  |  | 89.5 |
Segment Adjusted EBITDA | 262.3 |  |  | 243.7 |  |  | 518.9 |  |  | 476.3 |
Corporate and other | (21.6) |  |  | (24.5) |  |  | (48.4) |  |  | (42.4) |
Adjusted EBITDA | 240.7 |  |  | 219.2 |  |  | 470.5 |  |  | 433.9 |
- Interest expense | 13.3 |  |  | 9.5 |  |  | 26.4 |  |  | 19.0 |
- Depreciation | 14.4 |  |  | 12.5 |  |  | 27.2 |  |  | 24.7 |
- Amortization | 23.2 |  |  | 16.9 |  |  | 46.8 |  |  | 32.2 |
- Fair value inventory step-up charges | — |  |  | 0.4 |  |  | — |  |  | 0.4 |
- Restructuring expenses and asset impairments | 3.6 |  |  | 2.8 |  |  | 4.1 |  |  | 2.8 |
+ Gains on sales of assets | — |  |  | — |  |  | — |  |  | (2.7) |
- Credit loss on note receivable from collaborative partner(1) | 7.7 |  |  | — |  |  | 7.7 |  |  | — |
Income before income taxes | $ | 178.5 |  |  | $ | 177.1 |  |  | $ | 358.3 |  |  | $ | 357.5 |

(1) Represents a reserve on an investment with a collaborative partner that may no longer be recoverable. See Note 3 for further detail.

| June 30, 2023 |  | December 31, 2022
ASSETS |  |  |
Fluid & Metering Technologies | $ | 1,698.3 |  |  | $ | 1,676.9 |
Health & Science Technologies | 3,075.4 |  |  | 2,931.1 |
Fire & Safety/Diversified Products | 793.0 |  |  | 771.8 |
Corporate and other | 153.2 |  |  | 132.1 |
Total assets | $ | 5,719.9 |  |  | $ | 5,511.9 |

12

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
5. Revenue
Disaggregation of Revenue
The Company has a comprehensive offering of products, including technologies, built to customers’ specifications that are sold in niche markets throughout the world. The Company disaggregates its revenue from contracts with customers by reporting unit and geographical region for each segment as the Company believes it best depicts how the amount, nature, timing and uncertainty of its revenue and cash flows are affected by economic factors. Revenue was attributed to geographical region based on the location of the customer. The following tables present revenue disaggregated by reporting unit and geographical region.
Revenue by reporting unit for the three and six months ended June 30, 2023 and 2022 was as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30, |  |
| 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  |
Pumps | $ | 109.2 |  |  | $ | 104.5 |  |  | $ | 214.3 |  |  | $ | 201.9 |  |  |  |  |
Water | 87.3 |  |  | 81.6 |  |  | 181.4 |  |  | 146.0 |  |  |  |  |
Energy | 55.7 |  |  | 44.7 |  |  | 106.4 |  |  | 93.0 |  |  |  |  |
Agriculture | 40.1 |  |  | 38.1 |  |  | 78.7 |  |  | 70.4 |  |  |  |  |
Valves | 32.8 |  |  | 31.0 |  |  | 66.1 |  |  | 60.6 |  |  |  |  |
Intersegment elimination | (1.0) |  |  | (0.4) |  |  | (1.7) |  |  | (0.5) |  |  |  |  |
Fluid & Metering Technologies | 324.1 |  |  | 299.5 |  |  | 645.2 |  |  | 571.4 |  |  |  |  |
Scientific Fluidics & Optics | 169.0 |  |  | 149.2 |  |  | 347.6 |  |  | 290.4 |  |  |  |  |
Performance Pneumatic Technologies | 66.0 |  |  | 65.1 |  |  | 135.4 |  |  | 127.1 |  |  |  |  |
Sealing Solutions | 62.4 |  |  | 68.0 |  |  | 127.1 |  |  | 138.2 |  |  |  |  |
Material Processing Technologies | 33.0 |  |  | 34.8 |  |  | 60.7 |  |  | 68.5 |  |  |  |  |
Micropump | 9.1 |  |  | 8.9 |  |  | 19.7 |  |  | 17.0 |  |  |  |  |
Intersegment elimination | (1.1) |  |  | (0.6) |  |  | (1.8) |  |  | (1.2) |  |  |  |  |
Health & Science Technologies | 338.4 |  |  | 325.4 |  |  | 688.7 |  |  | 640.0 |  |  |  |  |
Fire & Safety | 109.8 |  |  | 99.8 |  |  | 216.0 |  |  | 195.5 |  |  |  |  |
Dispensing | 44.7 |  |  | 43.8 |  |  | 80.9 |  |  | 85.4 |  |  |  |  |
BAND-IT | 30.3 |  |  | 27.6 |  |  | 62.3 |  |  | 55.0 |  |  |  |  |
Intersegment elimination | (1.1) |  |  | — |  |  | (1.5) |  |  | (0.1) |  |  |  |  |
Fire & Safety/Diversified Products | 183.7 |  |  | 171.2 |  |  | 357.7 |  |  | 335.8 |  |  |  |  |
Net sales | $ | 846.2 |  |  | $ | 796.1 |  |  | $ | 1,691.6 |  |  | $ | 1,547.2 |  |  |  |  |

13

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Revenue by geographical region for the three and six months ended June 30, 2023 and 2022 was as follows:

| Three Months Ended June 30, 2023
| FMT |  | HST |  | FSDP |  | IDEX
U.S. | $ | 180.7 |  |  | $ | 148.5 |  |  | $ | 96.7 |  |  | $ | 425.9 |
North America, excluding U.S. | 17.9 |  |  | 8.2 |  |  | 8.1 |  |  | 34.2 |
Europe | 51.5 |  |  | 111.2 |  |  | 42.4 |  |  | 205.1 |
Asia | 48.8 |  |  | 65.2 |  |  | 28.0 |  |  | 142.0 |
Other (1) | 26.2 |  |  | 6.4 |  |  | 9.6 |  |  | 42.2 |
Intersegment elimination | (1.0) |  |  | (1.1) |  |  | (1.1) |  |  | (3.2) |
Net sales | $ | 324.1 |  |  | $ | 338.4 |  |  | $ | 183.7 |  |  | $ | 846.2 |

| Three Months Ended June 30, 2022
| FMT |  | HST |  | FSDP |  | IDEX
U.S. | $ | 170.5 |  |  | $ | 157.7 |  |  | $ | 85.0 |  |  | $ | 413.2 |
North America, excluding U.S. | 16.6 |  |  | 9.5 |  |  | 8.5 |  |  | 34.6 |
Europe | 51.8 |  |  | 92.5 |  |  | 42.0 |  |  | 186.3 |
Asia | 41.2 |  |  | 60.8 |  |  | 26.6 |  |  | 128.6 |
Other (1) | 19.8 |  |  | 5.5 |  |  | 9.1 |  |  | 34.4 |
Intersegment elimination | (0.4) |  |  | (0.6) |  |  | — |  |  | (1.0) |
Net sales | $ | 299.5 |  |  | $ | 325.4 |  |  | $ | 171.2 |  |  | $ | 796.1 |

| Six Months Ended June 30, 2023
| FMT |  | HST |  | FSDP |  | IDEX
U.S. | $ | 357.5 |  |  | $ | 298.1 |  |  | $ | 186.1 |  |  | $ | 841.7 |
North America, excluding U.S. | 37.3 |  |  | 13.4 |  |  | 16.6 |  |  | 67.3 |
Europe | 110.7 |  |  | 232.1 |  |  | 87.1 |  |  | 429.9 |
Asia | 93.9 |  |  | 131.8 |  |  | 51.4 |  |  | 277.1 |
Other (1) | 47.5 |  |  | 15.1 |  |  | 18.0 |  |  | 80.6 |
Intersegment elimination | (1.7) |  |  | (1.8) |  |  | (1.5) |  |  | (5.0) |
Net sales | $ | 645.2 |  |  | $ | 688.7 |  |  | $ | 357.7 |  |  | $ | 1,691.6 |

| Six Months Ended June 30, 2022
| FMT |  | HST |  | FSDP |  | IDEX
U.S. | $ | 320.5 |  |  | $ | 309.7 |  |  | $ | 161.5 |  |  | $ | 791.7 |
North America, excluding U.S. | 33.9 |  |  | 17.0 |  |  | 19.4 |  |  | 70.3 |
Europe | 100.5 |  |  | 183.8 |  |  | 87.0 |  |  | 371.3 |
Asia | 77.7 |  |  | 119.6 |  |  | 50.0 |  |  | 247.3 |
Other (1) | 39.3 |  |  | 11.1 |  |  | 18.0 |  |  | 68.4 |
Intersegment elimination | (0.5) |  |  | (1.2) |  |  | (0.1) |  |  | (1.8) |
Net sales | $ | 571.4 |  |  | $ | 640.0 |  |  | $ | 335.8 |  |  | $ | 1,547.2 |

(1) Other includes: South America, Middle East, Australia and Africa.
14

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Performance Obligations
The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. Revenue from products and services transferred to customers at a point in time approximated 95% of total revenues in all periods presented. Revenue from products and services transferred to customers over time approximated 5% of total revenues in all periods presented.
Contract Balances
The timing of revenue recognition, billings and cash collections can result in customer receivables, advance payments or billings in excess of revenue recognized. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables on the Condensed Consolidated Balance Sheets. Amounts are billed in accordance with contractual terms or as work progresses. Unbilled amounts arise when the timing of billing differs from the timing of revenue recognized, such as when contract provisions require specific milestones to be met before a customer can be billed. Unbilled amounts primarily relate to performance obligations satisfied over time when the cost- to-cost method is utilized and the revenue recognized exceeds the amount billed to the customer as there is not yet a right to invoice in accordance with contractual terms. Unbilled amounts are recorded as a contract asset when the revenue associated with the contract is recognized prior to billing and derecognized when billed in accordance with the terms of the contract.
The composition of customer receivables was as follows:

| June 30, 2023 |  | December 31, 2022
Billed receivables | $ | 437.6 |  |  | $ | 421.3 |
Unbilled receivables | 9.5 |  |  | 10.0 |
Total customer receivables | $ | 447.1 |  |  | $ | 431.3 |

Advance payments, deposits and billings in excess of revenue recognized are included in deferred revenue which is classified as current or noncurrent based on the timing of when the Company expects to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on the Condensed Consolidated Balance Sheets. Advance payments and deposits represent contract liabilities and are recorded when customers remit contractual cash payments in advance of the Company satisfying performance obligations under contractual arrangements, including those with performance obligations satisfied over time. The Company generally receives advance payments from customers related to maintenance services which are recognized ratably over the service term. The Company also receives deposits from customers on certain orders which the Company recognizes as revenue at a point in time. Billings in excess of revenue recognized represent contract liabilities and primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and revenue cannot yet be recognized as the Company has not completed the corresponding performance obligation. Contract liabilities are derecognized when revenue is recognized and the performance obligation is satisfied.
The composition of deferred revenue was as follows:

| June 30, 2023 |  | December 31, 2022
Deferred revenue - current | $ | 51.3 |  |  | $ | 44.7 |
Deferred revenue - noncurrent | 12.6 |  |  | 15.0 |
Total deferred revenue | $ | 63.9 |  |  | $ | 59.7 |

6. Earnings Per Common Share
Diluted earnings per common share (“EPS”) attributable to IDEX is computed by dividing Net income attributable to IDEX by the weighted average number of shares of common stock (basic) plus common stock equivalents (diluted) outstanding during the period. Common stock equivalents consist of restricted stock, performance share units and stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method.
15

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
ASC 260, Earnings Per Share, concludes that all outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding shares of restricted stock are participating securities. Accordingly, Diluted EPS attributable to IDEX was computed using the two-class method prescribed by ASC 260.
Basic weighted average shares outstanding reconciles to diluted weighted average shares outstanding as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Basic weighted average common shares outstanding | 75.6 |  |  | 75.8 |  |  | 75.6 |  |  | 76.0 |
Dilutive effect of stock options, restricted stock and performance share units | 0.3 |  |  | 0.3 |  |  | 0.3 |  |  | 0.2 |
Diluted weighted average common shares outstanding | 75.9 |  |  | 76.1 |  |  | 75.9 |  |  | 76.2 |

Options to purchase approximately 0.2 million and 0.5 million shares of common stock for the three months ended June 30, 2023 and 2022, respectively, and 0.2 million and 0.5 million shares of common stock for the six months ended June 30, 2023 and 2022, respectively, were not included in the computation of Diluted EPS attributable to IDEX because the effect of their inclusion would have been antidilutive.
16

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
7. Balance Sheet Components

| June 30, 2023 |  | December 31, 2022
INVENTORIES |  |  |
Raw materials and component parts | $ | 313.3 |  |  | $ | 301.2 |
Work in process | 50.5 |  |  | 54.3 |
Finished goods | 118.7 |  |  | 115.4 |
Total inventories | $ | 482.5 |  |  | $ | 470.9 |
ACCRUED EXPENSES |  |  |
Payroll and related items | $ | 83.7 |  |  | $ | 102.7 |
Management incentive compensation | 8.9 |  |  | 26.4 |
Income taxes payable | 19.2 |  |  | 30.2 |
Insurance | 10.7 |  |  | 11.2 |
Warranty | 8.2 |  |  | 8.1 |
Deferred revenue | 51.3 |  |  | 44.7 |
Lease liability | 21.6 |  |  | 21.6 |
Restructuring | 1.8 |  |  | 1.4 |
Accrued interest | 5.7 |  |  | 5.5 |
Pension and retiree medical obligations | 3.3 |  |  | 3.3 |
Other | 33.5 |  |  | 34.0 |
Total accrued expenses | $ | 247.9 |  |  | $ | 289.1 |
OTHER NONCURRENT LIABILITIES |  |  |
Pension and retiree medical obligations | $ | 55.0 |  |  | $ | 55.1 |
Transition tax payable | 5.0 |  |  | 9.1 |
Deferred revenue | 12.6 |  |  | 15.0 |
Lease liability | 101.6 |  |  | 96.6 |
Other | 22.6 |  |  | 20.0 |
Total other noncurrent liabilities | $ | 196.8 |  |  | $ | 195.8 |

8. Goodwill and Intangible Assets
The changes in the carrying amount of goodwill for the six months ended June 30, 2023, by reportable business segment, were as follows:

| FMT |  | HST |  | FSDP |  | IDEX
Goodwill | $ | 800.9 |  |  | $ | 1,644.8 |  |  | $ | 393.0 |  |  | $ | 2,838.7 |
Accumulated goodwill impairment losses | (20.7) |  |  | (149.8) |  |  | (30.1) |  |  | (200.6) |
Balance at January 1, 2023 | 780.2 |  |  | 1,495.0 |  |  | 362.9 |  |  | 2,638.1 |
Foreign currency translation | 3.4 |  |  | 16.2 |  |  | 3.1 |  |  | 22.7 |
Acquisitions | — |  |  | 53.6 |  |  | — |  |  | 53.6 |
Acquisition adjustments | (1.8) |  |  | 1.8 |  |  | — |  |  | — |
Balance at June 30, 2023 | $ | 781.8 |  |  | $ | 1,566.6 |  |  | $ | 366.0 |  |  | $ | 2,714.4 |

ASC 350, Goodwill and Other Intangible Assets, requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. In the first six months of 2023, there were no events or
17

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
circumstances that would have required an interim impairment test. Annually, on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. Based on the results of the Company’s annual impairment test at October 31, 2022, all reporting units had fair values in excess of their carrying values.
The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at June 30, 2023 and December 31, 2022:

| At June 30, 2023 |  | At December 31, 2022
| Gross Carrying Amount |  | Accumulated Amortization |  | Net |  | Weighted Average Life |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net
Amortized intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Patents | $ | 2.9 |  |  | $ | (2.0) |  |  | $ | 0.9 |  |  | 12 |  | $ | 2.9 |  |  | $ | (1.8) |  |  | $ | 1.1 |
Trade names | 194.5 |  |  | (79.7) |  |  | 114.8 |  |  | 15 |  | 186.5 |  |  | (71.4) |  |  | 115.1 |
Customer relationships | 805.6 |  |  | (212.4) |  |  | 593.2 |  |  | 13 |  | 772.2 |  |  | (184.9) |  |  | 587.3 |
Unpatented technology | 214.3 |  |  | (60.4) |  |  | 153.9 |  |  | 12 |  | 207.1 |  |  | (57.8) |  |  | 149.3 |
Software | 4.9 |  |  | (1.3) |  |  | 3.6 |  |  | 5 |  | 4.8 |  |  | (0.7) |  |  | 4.1 |
Total amortized intangible assets | 1,222.2 |  |  | (355.8) |  |  | 866.4 |  |  |  |  | 1,173.5 |  |  | (316.6) |  |  | 856.9 |
Indefinite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Banjo trade name | 62.1 |  |  | — |  |  | 62.1 |  |  |  |  | 62.1 |  |  | — |  |  | 62.1 |
Akron Brass trade name | 28.8 |  |  | — |  |  | 28.8 |  |  |  |  | 28.8 |  |  | — |  |  | 28.8 |
Total intangible assets | $ | 1,313.1 |  |  | $ | (355.8) |  |  | $ | 957.3 |  |  |  |  | $ | 1,264.4 |  |  | $ | (316.6) |  |  | $ | 947.8 |

The Banjo trade name and the Akron Brass trade name are indefinite-lived intangible assets which are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the assets might be impaired. Based on the results of the Company’s annual impairment test at October 31, 2022, these indefinite-lived intangible assets had fair values in excess of their carrying values. In the first six months of 2023, there were no events or circumstances that would have required an interim impairment test on these indefinite-lived intangible assets.
Amortization of intangible assets was $23.2 million and $46.8 million for the three and six months ended June 30, 2023, respectively. Amortization of intangible assets wa s $16.9 million and $32.2 million for the three and six months ended June 30, 2022, respectively. Based on the intangible asset balances as of June 30, 2023, expected amortization expense for the remaining six months of 2023 and for the years 2024 through 2027 is as follows:

Maturity of Intangible Assets |  | Estimated Amortization
2023 (excluding the six months ended June 30, 2023) |  | $ | 47.7 |
2024 |  | 91.6 |
2025 |  | 90.2 |
2026 |  | 88.5 |
2027 |  | 84.5 |

18

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
9. Borrowings
Borrowings at June 30, 2023 and December 31, 2022 consisted of the following:

| June 30, 2023 |  | December 31, 2022
3.20% Senior Notes, due June 2023 | $ | — |  |  | $ | 100.0 |
3.37% Senior Notes, due June 2025 | 100.0 |  |  | 100.0 |
5.13% Senior Notes, due June 2028 | 100.0 |  |  | — |
3.00% Senior Notes, due May 2030 | 500.0 |  |  | 500.0 |
2.625% Senior Notes, due June 2031 | 500.0 |  |  | 500.0 |
$800.0 million Revolving Credit Facility, due November 2027(1) | 79.5 |  |  | 77.7 |
$200.0 million Term Facility, due November 2027(2) | 200.0 |  |  | 200.0 |
Other borrowings | 1.0 |  |  | 0.1 |
Total borrowings | 1,480.5 |  |  | 1,477.8 |
Less current portion | 0.5 |  |  | — |
Less deferred debt issuance costs | 7.4 |  |  | 7.9 |
Less unaccreted debt discount | 1.1 |  |  | 1.2 |
Long-term borrowings | $ | 1,471.5 |  |  | $ | 1,468.7 |

(1) At June 30, 2023, there was $79.5 million outstanding under the Revolving Credit Facility with an interest rate of 4.32% and $7.4 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Credit Facility of approximately $713.1 million.
(2) The $200.0 million outstanding under the Term Facility bears an interest rate of 6.30%.
At June 30, 2023, the Company was in compliance with covenants contained in the credit agreement associated with the Revolving Credit Facility as well as other long-term debt agreements.
Issuance of 5.13% Senior Notes in 2023
On June 13, 2023, the Company completed a private placement of $100 million aggregate principal amount of 5.13% Senior Notes due June 13, 2028 (the “5.13% Senior Notes”) pursuant to a Note Purchase and Master Note Agreement, dated as of June 13, 2023 (the “Purchase Agreement”), among the Company, NYL Investors LLC (“New York Life”) and certain affiliates of New York Life identified as Purchasers of the 5.13% Senior Notes therein. The 5.13% Senior Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other unsecured, unsubordinated debt. The Company used the proceeds from the 5.13% Senior Notes issuance to repay the 3.20% Senior Notes due June 13, 2023.
The Company may at any time prepay all, or any portion of the 5.13% Senior Notes, provided that such portion is not less than 5% of the aggregate principal amount of all notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole amount. The Company also has the ability to make certain other offers to repurchase any notes outstanding under the Purchase Agreement.
The Purchase Agreement contains certain covenants that restrict the Company’s and its subsidiaries’ ability to, among other things, transfer or sell assets, create liens, incur indebtedness, transact with affiliates and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio, interest coverage ratio and priority debt ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all notes then outstanding under the Purchase Agreement will become due and payable immediately without further action or notice. In the case of payment events of default, any holder of such notes affected thereby may declare all of the notes outstanding under the Purchase Agreement held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the notes then outstanding under the
19

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Purchase Agreement may declare all of such notes to be due and payable immediately, in each case subject to certain cure and notice provisions.
10. Fair Value Measurements
ASC 820, Fair Value Measurements and Disclosures, defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
•Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheets at June 30, 2023 and December 31, 2022:

| Basis of Fair Value Measurements
| Balance at June 30, 2023 |  | Level 1 |  | Level 2 |  | Level 3
Trading securities - mutual funds held in nonqualified SERP(1) | $ | 9.4 |  |  | $ | 9.4 |  |  | $ | — |  |  | $ | — |
Available-for-sale securities - equities(2) | 19.1 |  |  | 19.1 |  |  | — |  |  | — |

| Basis of Fair Value Measurements
| Balance at December 31, 2022 |  | Level 1 |  | Level 2 |  | Level 3
Trading securities - mutual funds held in nonqualified SERP(1) | $ | 7.5 |  |  | $ | 7.5 |  |  | $ | — |  |  | $ | — |

(1) The Supplemental Executive Retirement Plan (“SERP”) investment assets are offset by a SERP liability which represents the Company’s obligation to distribute SERP funds to participants.
(2) At June 30, 2023, the securities are included in Other current assets on the Company’s Condensed Consolidated Balance Sheets and are available for overnight cash settlement, if necessary, to fund current operations.
There were no transfers of assets or liabilities between Level 1 and Level 2 during the three and six months ended June 30, 2023 or the year ended December 31, 2022.
The carrying values of the Company’s cash and cash equivalents, accounts receivable, marketable securities, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. At June 30, 2023 and December 31, 2022, the fair value of the outstanding indebtedness described in Note 9 based on quoted market prices and current market rates for debt with similar credit risk and maturity was approximately $1,333.3 million and $1,328.7 million, respectively, compared to the carrying value of $1,479.4 million and $1,476.6 million, respectively. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to the Company’s rating.
20

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
11. Leases
The Company leases certain office facilities, warehouses, manufacturing plants, equipment (which includes both office and plant equipment) and vehicles under operating leases and certain plant equipment under financing leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.
Certain leases include one or more options to renew. The exercise of lease renewal options is at the Company’s sole discretion. The Company does not include renewal periods in any of the leases’ terms until the renewal is executed as they are generally not reasonably certain of being exercised. The Company does not have any material purchase options.
Certain of the Company’s lease agreements have rental payments that are adjusted periodically for inflation or that are based on usage. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Supplemental balance sheet information related to leases as of June 30, 2023 and December 31, 2022 was as follows:

| Balance Sheet Caption |  | June 30, 2023 |  | December 31, 2022
Right-of-Use (“ROU”) Assets: |  |  |  |  |
Building ROU assets - net - operating | Other noncurrent assets |  | $ | 111.5 |  |  | $ | 104.4 |
Equipment ROU assets - net - operating | Other noncurrent assets |  | 5.0 |  |  | 5.6 |
Equipment ROU assets - net - financing | Property, plant and equipment |  | 2.0 |  |  | 6.1 |
Total ROU assets - net |  |  | $ | 118.5 |  |  | $ | 116.1 |
Lease Liabilities: |  |  |  |  |
Current lease liabilities | Accrued expenses |  | $ | 21.6 |  |  | $ | 21.6 |
Noncurrent lease liabilities | Other noncurrent liabilities |  | 101.6 |  |  | 96.6 |
Total lease liabilities |  |  | $ | 123.2 |  |  | $ | 118.2 |

The components of lease cost for the three and six months ended June 30, 2023 and 2022 were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Fixed lease cost (1) | $ | 7.5 |  |  | $ | 9.0 |  |  | $ | 15.7 |  |  | $ | 16.4 |
Variable lease cost | 0.6 |  |  | 0.8 |  |  | 1.3 |  |  | 1.2 |
Total lease cost | $ | 8.1 |  |  | $ | 9.8 |  |  | $ | 17.0 |  |  | $ | 17.6 |

(1) Includes short-term leases, which are immaterial.
Supplemental cash flow information related to leases for the six months ended June 30, 2023 and 2022 was as follows:

| Six Months Ended June 30,
| 2023 |  | 2022
Cash paid for amounts included in the measurement of lease liabilities | $ | 15.7 |  |  | $ | 16.9 |
Right-of-use assets obtained in exchange for new lease liabilities | 17.1 |  |  | 9.3 |

21

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Other supplemental information related to leases as of June 30, 2023 and December 31, 2022 was as follows:

Lease Term and Discount Rate | June 30, 2023 |  | December 31, 2022 |  |
Weighted-average remaining lease term (years): |  |  |  |  |
Operating leases - building and equipment | 7.28 |  | 7.43 |  |
Operating leases - vehicles | 2.13 |  | 2.14 |  |
Financing leases - equipment | 4.10 |  | 2.05 |  |
Weighted-average discount rate: |  |  |  |  |
Operating leases - building and equipment | 3.66 | % |  | 3.41 | % |  |
Operating leases - vehicles | 2.46 | % |  | 1.70 | % |  |
Financing leases - equipment | 4.96 | % |  | 4.48 | % |  |

The Company uses its incremental borrowing rate to determine the present value of the lease payments.
Total lease liabilities at June 30, 2023 have scheduled maturities as follows:

Maturity of Lease Liabilities |  |
2023 (excluding the six months ended June 30, 2023) |  | $ | 12.8 |
2024 |  | 19.6 |
2025 |  | 22.3 |
2026 |  | 19.4 |
2027 |  | 15.7 |
Thereafter |  | 52.1 |
Total lease payments |  | 141.9 |
Less: Imputed interest |  | (18.7) |
Present value of lease liabilities |  | $ | 123.2 |

12. Restructuring Expenses and Asset Impairments
From time to time, the Company incurs expenses to facilitate long-term sustainable growth through cost reduction actions, consisting of employee reductions, facility rationalization and contract termination costs. These costs include severance costs, exit costs and asset impairments and are included in Restructuring expenses and asset impairments in the Condensed Consolidated Statements of Income. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs and employer tax liabilities, while exit costs primarily consist of lease exit and contract termination costs.
2023 Initiative
During the three and six months ended June 30, 2023, the Company incurred severance costs related to employee reductions as well as asset impairment charges.
Pre-tax restructuring expenses and asset impairments by segment for the three and six months ended June 30, 2023 were as follows:
22

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

|  | Three Months Ended June 30, 2023
|  | Severance Costs |  | Exit Costs |  | Asset Impairments |  | Total
Fluid & Metering Technologies |  | $ | 0.1 |  |  | $ | — |  |  | $ | 0.5 |  |  | $ | 0.6 |
Health & Science Technologies |  | 2.7 |  |  | — |  |  | — |  |  | 2.7 |
Fire & Safety/Diversified Products |  | 0.3 |  |  | — |  |  | — |  |  | 0.3 |
Corporate/Other |  | — |  |  | — |  |  | — |  |  | — |
Restructuring expenses and asset impairments |  | $ | 3.1 |  |  | $ | — |  |  | $ | 0.5 |  |  | $ | 3.6 |

|  | Six Months Ended June 30, 2023
|  | Severance Costs |  | Exit Costs |  | Asset Impairments |  | Total
Fluid & Metering Technologies |  | $ | 0.2 |  |  | $ | — |  |  | $ | 0.5 |  |  | $ | 0.7 |
Health & Science Technologies |  | 3.0 |  |  | — |  |  | — |  |  | 3.0 |
Fire & Safety/Diversified Products |  | 0.4 |  |  | — |  |  | — |  |  | 0.4 |
Corporate/Other |  | — |  |  | — |  |  | — |  |  | — |
Restructuring expenses and asset impairments |  | $ | 3.6 |  |  | $ | — |  |  | $ | 0.5 |  |  | $ | 4.1 |

2022 Initiative
During the three and six months ended June 30, 2022, the Company primarily incurred severance costs related to employee reductions.
Pre-tax restructuring expenses and asset impairments by segment for the three and six months ended June 30, 2022 were as follows:

|  | Three Months Ended June 30, 2022
|  | Severance Costs |  | Exit Costs |  | Asset Impairments |  | Total
Fluid & Metering Technologies |  | $ | 1.2 |  |  | $ | 0.3 |  |  | $ | 0.2 |  |  | $ | 1.7 |
Health & Science Technologies |  | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Fire & Safety/Diversified Products |  | 1.0 |  |  | — |  |  | — |  |  | 1.0 |
Corporate/Other |  | — |  |  | — |  |  | — |  |  | — |
Restructuring expenses and asset impairments |  | $ | 2.3 |  |  | $ | 0.3 |  |  | $ | 0.2 |  |  | $ | 2.8 |

|  | Six Months Ended June 30, 2022
|  | Severance Costs |  | Exit Costs |  | Asset Impairments |  | Total
Fluid & Metering Technologies |  | $ | 1.5 |  |  | $ | 0.3 |  |  | $ | 0.2 |  |  | $ | 2.0 |
Health & Science Technologies |  | 0.2 |  |  | — |  |  | — |  |  | 0.2 |
Fire & Safety/Diversified Products |  | 1.0 |  |  | — |  |  | — |  |  | 1.0 |
Corporate/Other |  | 0.2 |  |  | — |  |  | — |  |  | 0.2 |
Restructuring expenses and asset impairments |  | $ | 2.9 |  |  | $ | 0.3 |  |  | $ | 0.2 |  |  | $ | 3.4 |

Restructuring accruals reflected in Accrued expenses in the Company’s Condensed Consolidated Balance Sheets are as follows:
23

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)

| Restructuring Initiatives
Balance at January 1, 2023 | $ | 1.4 |
Restructuring expenses | 3.6 |
Payments, utilization and other | (3.2) |
Balance at June 30, 2023 | $ | 1.8 |

13. Other Comprehensive Income (Loss)
The components of Other comprehensive income (loss) are as follows:

| Three Months Ended June 30, 2023 |  | Three Months Ended June 30, 2022
| Pre-tax |  | Tax |  | Net of tax |  | Pre-tax |  | Tax |  | Net of tax
Cumulative translation adjustment | $ | 2.3 |  |  | $ | — |  |  | $ | 2.3 |  |  | $ | (81.9) |  |  | $ | — |  |  | $ | (81.9) |
Pension and other postretirement adjustments | (1.3) |  |  | 0.4 |  |  | (0.9) |  |  | 1.1 |  |  | (0.5) |  |  | 0.6 |
Total other comprehensive income (loss) | $ | 1.0 |  |  | $ | 0.4 |  |  | $ | 1.4 |  |  | $ | (80.8) |  |  | $ | (0.5) |  |  | $ | (81.3) |

| Six Months Ended June 30, 2023 |  | Six Months Ended June 30, 2022
| Pre-tax |  | Tax |  | Net of tax |  | Pre-tax |  | Tax |  | Net of tax
Cumulative translation adjustment | $ | 38.9 |  |  | $ | — |  |  | $ | 38.9 |  |  | $ | (101.4) |  |  | $ | — |  |  | $ | (101.4) |
Pension and other postretirement adjustments | (0.7) |  |  | 0.2 |  |  | (0.5) |  |  | 1.9 |  |  | (0.7) |  |  | 1.2 |
Total other comprehensive income (loss) | $ | 38.2 |  |  | $ | 0.2 |  |  | $ | 38.4 |  |  | $ | (99.5) |  |  | $ | (0.7) |  |  | $ | (100.2) |

The amounts reclassified from Accumulated other comprehensive loss to Net income during the three and six months ended June 30, 2023 and 2022 are as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30, |
| 2023 |  | 2022 |  | 2023 |  | 2022 | Income Statement Caption
Pension and other postretirement plans: |  |  |  |  |  |  |  |
Amortization of actuarial (gains) losses and prior service costs | $ | (1.3) |  |  | $ | 1.1 |  |  | $ | (0.7) |  |  | $ | 1.9 |  | Other expense (income) - net
Total before tax | (1.3) |  |  | 1.1 |  |  | (0.7) |  |  | 1.9 |  |
Provision for income taxes | 0.4 |  |  | (0.5) |  |  | 0.2 |  |  | (0.7) |  |
Total net of tax | $ | (0.9) |  |  | $ | 0.6 |  |  | $ | (0.5) |  |  | $ | 1.2 |  |

14. Share Repurchases
On March 17, 2020, the Company’s Board of Directors approved an increase of $500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorization of the Board of Directors of $300.0 million on December 1, 2015. These authorizations have no expiration date. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Credit Facility. During the six months ended June 30, 2023, the Company repurchased a total of 5,400 shares at a cost of $1.1 million, of which $0.1 million was settled in July 2023. During the six months ended June 30, 2022, the Company repurchased a total of 622,190 shares at a cost of $115.8 million, of which $5.4 million was settled in July 2022. As of June 30, 2023, the amount of share repurchase authorization remaining was $562.8 million.
24

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
15. Share-Based Compensation
The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Board of Directors based on the recommendation from the Compensation Committee.
The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of stock compensation cost within the Condensed Consolidated Statements of Income is consistent with the classification of cash compensation for the same employees.
Stock Options
Stock options granted under the Company’s plans are generally non-qualified and are granted with an exercise price equal to the market price of the Company’s stock on the date of grant. The fair value of each option grant was estimated on the date of the grant using the Black Scholes valuation model. Stock options generally vest ratably over four years, with vesting beginning one year from the date of grant, and generally expire 10 years from the date of grant. The service period for certain retiree eligible participants is accelerated. Weighted average stock option fair values and assumptions for the periods presented are disclosed below.

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Weighted average fair value of grants | $57.13 |  | $46.33 |  | $60.70 |  | $41.74
Dividend yield | 1.13% |  | 1.14% |  | 1.07% |  | 1.14%
Volatility | 27.20% |  | 25.39% |  | 27.19% |  | 25.15%
Risk-free interest rate | 3.81% |  | 2.98% |  | 4.12% |  | 1.85%
Expected life (in years) | 4.50 |  | 4.90 |  | 4.50 |  | 4.90

Total compensation cost for stock options is recorded in the Condensed Consolidated Statements of Income as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Cost of goods sold | $ | 0.1 |  |  | $ | — |  |  | $ | 0.4 |  |  | $ | 0.3 |
Selling, general and administrative expenses(1) | 1.4 |  |  | 2.8 |  |  | 7.1 |  |  | 5.9 |
Total expense before income taxes | 1.5 |  |  | 2.8 |  |  | 7.5 |  |  | 6.2 |
Income tax benefit | (0.2) |  |  | (0.2) |  |  | (0.6) |  |  | (0.5) |
Total expense after income taxes | $ | 1.3 |  |  | $ | 2.6 |  |  | $ | 6.9 |  |  | $ | 5.7 |

(1) The three months ended June 30, 2023 include $1.5 million of lower expense compared with the same period in 2022 while the six months ended June 30, 2023 include $1.1 million of higher expense compared with the same period in 2022 as it relates to the timing of accelerated stock compensation costs for retiree eligible participants.
25

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
A summary of the Company’s stock option activity as of June 30, 2023 and changes during the six months ended June 30, 2023 are presented in the following table:

Stock Options | Shares |  | Weighted Average Price |  | Weighted-Average Remaining Contractual Term |  | Aggregate Intrinsic Value
| (Dollars in millions except weighted average price)
Outstanding at January 1, 2023 | 1,015,572 |  |  | $ | 161.45 |  |  | 6.94 |  | $ | 67.9 |
Granted | 213,865 |  |  | 225.52 |  |  |  |  |
Exercised | (59,643) |  |  | 134.89 |  |  |  |  |
Forfeited | (22,370) |  |  | 198.67 |  |  |  |  |
Outstanding at June 30, 2023 | 1,147,424 |  |  | $ | 174.05 |  |  | 7.09 |  | $ | 49.5 |
Vested and expected to vest as of June 30, 2023 | 1,103,113 |  |  | $ | 172.66 |  |  | 7.01 |  | $ | 49.0 |
Exercisable at June 30, 2023 | 617,095 |  |  | $ | 148.13 |  |  | 5.69 |  | $ | 41.5 |

As of June 30, 2023, there was $12.3 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.5 years.
Restricted Stock
Restricted stock awards generally cliff vest after three years for employees and non-employee directors. The service period for certain retiree eligible participants is accelerated. Unvested restricted stock carries dividend and voting rights and the sale of the shares is restricted prior to the date of vesting. Dividends are paid on restricted stock awards and their fair value is equal to the market price of the Company’s stock at the date of the grant. A summary of the Company’s restricted stock activity as of June 30, 2023 and changes during the six months ended June 30, 2023 are presented in the following table:

Restricted Stock | Shares |  | Weighted-Average Grant Date Fair Value
Unvested at January 1, 2023 | 104,382 |  |  | $ | 179.45 |
Granted | 35,845 |  |  | 219.69 |
Vested | (20,802) |  |  | 170.41 |
Forfeited | (9,150) |  |  | 202.31 |
Unvested at June 30, 2023 | 110,275 |  |  | $ | 192.34 |

Total compensation cost for restricted stock is recorded in the Condensed Consolidated Statements of Income as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Cost of goods sold | $ | 0.1 |  |  | $ | — |  |  | $ | 0.3 |  |  | $ | 0.2 |
Selling, general and administrative expenses | 1.6 |  |  | 1.6 |  |  | 3.0 |  |  | 3.2 |
Total expense before income taxes | 1.7 |  |  | 1.6 |  |  | 3.3 |  |  | 3.4 |
Income tax benefit | (0.4) |  |  | (0.2) |  |  | (0.7) |  |  | (0.6) |
Total expense after income taxes | $ | 1.3 |  |  | $ | 1.4 |  |  | $ | 2.6 |  |  | $ | 2.8 |

As of June 30, 2023, there was $7.9 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 1.1 years.
26

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
Cash-Settled Restricted Stock
The Company also maintains a cash-settled share-based compensation plan for certain employees. Cash-settled restricted stock awards generally cliff vest after three years. The service period for certain retiree eligible participants is accelerated. Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company’s stock on the last day of the quarter. Dividend equivalents are paid on certain cash-settled restricted stock awards. A summary of the Company’s unvested cash-settled restricted stock activity as of June 30, 2023 and changes during the six months ended June 30, 2023 are presented in the following table:

Cash-Settled Restricted Stock | Shares |  | Weighted-Average Fair Value
Unvested at January 1, 2023 | 57,356 |  |  | $ | 228.33 |
Granted | 19,970 |  |  | 225.53 |
Vested | (15,481) |  |  | 229.12 |
Forfeited | (1,985) |  |  | 215.26 |
Unvested at June 30, 2023 | 59,860 |  |  | $ | 215.26 |

Total compensation cost for cash-settled restricted stock is recorded in the Condensed Consolidated Statements of Income as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Cost of goods sold | $ | 0.1 |  |  | $ | 0.1 |  |  | $ | 0.2 |  |  | $ | — |
Selling, general and administrative expenses | 0.5 |  |  | (0.5) |  |  | 1.5 |  |  | — |
Total expense before income taxes | 0.6 |  |  | (0.4) |  |  | 1.7 |  |  | — |
Income tax benefit | (0.1) |  |  | — |  |  | (0.1) |  |  | — |
Total expense after income taxes | $ | 0.5 |  |  | $ | (0.4) |  |  | $ | 1.6 |  |  | $ | — |

As of June 30, 2023, there was $5.7 million of total unrecognized compensation cost related to cash-settled restricted shares that is expected to be recognized over a weighted-average period of 1.2 years.
Performance Share Units
Weighted average performance share unit fair values and assumptions for the periods specified are disclosed below. The performance share units are market condition awards and have been assessed at fair value on the date of grant using a Monte Carlo simulation model.

| Six Months Ended June 30,
| 2023 |  | 2022
Weighted average fair value of grants | $308.18 |  | $235.54
Dividend yield | —% |  | —%
Volatility | 27.00% |  | 28.09%
Risk-free interest rate | 4.37% |  | 1.73%
Expected life (in years) | 2.94 |  | 2.93

27

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
A summary of the Company’s performance share unit activity as of June 30, 2023 and changes during the six months ended June 30, 2023 are presented in the following table:

Performance Share Units | Shares |  | Weighted-Average Grant Date Fair Value
Unvested at January 1, 2023 | 70,915 |  |  | $ | 236.66 |
Granted | 28,030 |  |  | 308.18 |
Vested | (18,105) |  |  | 226.86 |
Forfeited | (1,725) |  |  | 261.13 |
Unvested at June 30, 2023 | 79,115 |  |  | $ | 264.89 |

On January 31, 2023, 18,105 performance share units vested. Based on the Company’s relative total shareholder return rank during the three year period ended January 31, 2023, the Company achieved a 173% payout factor and issued 31,334 common shares in February 2023 for awards that vested in 2023.
Total compensation cost for performance share units is recorded in the Condensed Consolidated Statements of Income as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Cost of goods sold | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Selling, general and administrative expenses(1) | 0.8 |  |  | 2.5 |  |  | 6.0 |  |  | 3.8 |
Total expense before income taxes | 0.8 |  |  | 2.5 |  |  | 6.0 |  |  | 3.8 |
Income tax benefit | (0.1) |  |  | — |  |  | (0.2) |  |  | (0.1) |
Total expense after income taxes | $ | 0.7 |  |  | $ | 2.5 |  |  | $ | 5.8 |  |  | $ | 3.7 |

(1) The three months ended June 30, 2023 include $1.8 million of lower expense compared with the same period in 2022 while the six months ended June 30, 2023 include $1.6 million of higher expense compared with the same period in 2022 as it relates to the timing of accelerated stock compensation costs for retiree eligible participants.
As of June 30, 2023, there was $4.9 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.1 years.
28

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
16. Retirement Benefits
The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans as well as other post-retirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.

| Pension Benefits
| Three Months Ended June 30,
| 2023 |  | 2022
| U.S. |  | Non-U.S. |  | U.S. |  | Non-U.S.
Service cost | $ | — |  |  | $ | 0.3 |  |  | $ | 0.1 |  |  | $ | 0.4 |
Interest cost | 0.1 |  |  | 0.7 |  |  | — |  |  | 0.3 |
Expected return on plan assets | — |  |  | (0.4) |  |  | — |  |  | (0.3) |
Net amortization | — |  |  | (0.1) |  |  | — |  |  | 0.2 |
Net periodic cost | $ | 0.1 |  |  | $ | 0.5 |  |  | $ | 0.1 |  |  | $ | 0.6 |

| Pension Benefits
| Six Months Ended June 30,
| 2023 |  | 2022
| U.S. |  | Non-U.S. |  | U.S. |  | Non-U.S.
Service cost | $ | — |  |  | $ | 0.6 |  |  | $ | 0.1 |  |  | $ | 0.9 |
Interest cost | 0.2 |  |  | 1.4 |  |  | 0.1 |  |  | 0.5 |
Expected return on plan assets | (0.1) |  |  | (0.8) |  |  | (0.1) |  |  | (0.6) |
Net amortization | 0.1 |  |  | (0.3) |  |  | 0.1 |  |  | 0.4 |
Net periodic cost | $ | 0.2 |  |  | $ | 0.9 |  |  | $ | 0.2 |  |  | $ | 1.2 |

| Other Postretirement Benefits
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Service cost | $ | 0.1 |  |  | $ | 0.1 |  |  | $ | 0.2 |  |  | $ | 0.3 |
Interest cost | 0.2 |  |  | 0.2 |  |  | 0.4 |  |  | 0.3 |
Net amortization | (0.3) |  |  | (0.1) |  |  | (0.5) |  |  | (0.2) |
Net periodic cost | $ | — |  |  | $ | 0.2 |  |  | $ | 0.1 |  |  | $ | 0.4 |

The Company expects to contribute approximately $3.9 million to its defined benefit plans and $1.1 million to its other post-retirement benefit plans in 2023. During the first six months of 2023, the Company contributed a total of $2.6 million to fund these plans.
29

Table of Contents
IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share amounts)
(unaudited)
17. Legal Proceedings
The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings arising in the ordinary course of business. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company’s business, financial condition, results of operations or cash flows.
18. Income Taxes
The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to $40.0 million for the three months ended June 30, 2023 from $39.0 million during the same period in 2022. The effective tax rate of 22.4% for the three months ended June 30, 2023 was relatively consistent with 22.1% during the same period in 2022.
The provision for income taxes increased to $80.0 million for the six months ended June 30, 2023 from $79.5 million during the same period in 2022. The effective tax rate of 22.3% for the six months ended June 30, 2023 was relatively consistent with 22.2% during the same period in 2022.
30

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and related notes in this quarterly report. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company’s actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under Item 1A, “Risk Factors” in the Company’s most recent annual report on Form 10-K and under the heading “Cautionary Statement Under the Private Securities Litigation Reform Act” discussed elsewhere in this quarterly report.
This discussion also includes certain non-GAAP financial measures that have been defined and reconciled to their most directly comparable measures that are in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) later in this Item under the headings “Non-GAAP Disclosures” and “Free Cash Flow.” This discussion also includes Operating working capital, which has been defined later in this Item under the heading “Liquidity and Capital Resources.” The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.
Overview
IDEX is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business and by the relationship of the U.S. dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are important factors that influence the demand for IDEX’s products.
Select key financial results for the three months ended June 30, 2023 when compared to the same period in the prior year are as follows:

| Three Months Ended June 30, |  |
(Dollars in millions, except per share amounts) | 2023 |  | 2022 |  | % / bps Change |  |  |  |  |  |
Net sales | $ | 846.2 |  | $ | 796.1 |  | 6% |  |  |  |  |  |
Organic net sales growth* |  |  |  |  | 3% |  |  |  |  |  |
Net income attributable to IDEX | 138.6 |  | 138.2 |  | — |  |  |  |  |  |
Adjusted net income attributable to IDEX* | 165.4 |  | 153.6 |  | 8% |  |  |  |  |  |
Adjusted EBITDA* | 240.7 |  | 219.2 |  | 10% |  |  |  |  |  |
Diluted EPS attributable to IDEX | 1.82 |  | 1.81 |  | 1% |  |  |  |  |  |
Adjusted diluted EPS attributable to IDEX* | 2.18 |  | 2.02 |  | 8% |  |  |  |  |  |
Cash flows from operating activities | 141.2 |  | 112.3 |  | 26% |  |  |  |  |  |
Free cash flow* | 119.6 |  | 96.7 |  | 24% |  |  |  |  |  |
Net income margin | 16.4% |  | 17.3% |  | (90) bps |  |  |  |  |  |
Adjusted EBITDA margin* | 28.4% |  | 27.5% |  | 90 bps |  |  |  |  |  |

*These are non-GAAP measures. See the definitions of these non-GAAP measures and reconciliations to their most directly comparable GAAP financial measures later in this Item under the headings “Non-GAAP Disclosures” and “Free Cash Flow”.
During the three months ended June 30, 2023, the Company achieved record sales of $846.2 million, up 6% overall and 3% organically, led by strong performance by its FMT and FSDP segments compared with the same period in 2022. The HST segment revenues and profitability was challenged due to customers’ inventory recalibration within the Analytical Instrumentation, Life Science and Biopharma markets. The Company also achieved diluted earnings per share of $1.82, up 1%, and record adjusted earnings per share of $2.18, up 8%. The Company drove strong operating cash flow of $141.2 million, up 26% versus the comparable prior year period, and free cash flow of $119.6 million, up 24%, primarily due to lower investments in working capital. Lastly, the Company also completed the acquisition of Iridian, which will be reported as part of the Scientific Fluidic and Optics reporting unit in the HST segment.
In the second half of 2023, the Company currently expects revenues and earnings will be lower as compared to the first half of 2023 driven by market-based declines within both its FMT and HST segments.
31

Table of Contents
Results of Operations
The following is a discussion and analysis of the Company’s results of operations for the three and six months ended June 30, 2023 compared with the three and six months ended June 30, 2022.

| Three Months Ended June 30, |  | Six Months Ended June 30,
(Dollars in millions, except per share amounts) | 2023 |  | 2022 |  | % / bps Change |  | 2023 |  | 2022 |  | % / bps Change
Net sales | $ | 846.2 |  | $ | 796.1 |  | 6 | % |  | $ | 1,691.6 |  | $ | 1,547.2 |  | 9 | %
Cost of sales | 468.2 |  | 439.2 |  | 7 | % |  | 931.1 |  | 847.8 |  | 10 | %
Gross profit | 378.0 |  | 356.9 |  | 6 | % |  | 760.5 |  | 699.4 |  | 9 | %
Gross margin | 44.7 | % |  | 44.8 | % |  | (10) bps |  | 45.0 | % |  | 45.2 | % |  | (20) bps
Selling, general and administrative expenses | 174.3 |  | 167.5 |  | 4 | % |  | 364.0 |  | 321.8 |  | 13 | %
Restructuring expenses and asset impairments | 3.6 |  | 2.8 |  | 29 | % |  | 4.1 |  | 3.4 |  | 21 | %
Operating income | 200.1 |  | 186.6 |  | 7 | % |  | 392.4 |  | 374.2 |  | 5 | %
Other expense (income) - net | 8.3 |  | — |  | 100 | % |  | 7.7 |  | (2.3) |  | (435 | %)
Interest expense | 13.3 |  | 9.5 |  | 40 | % |  | 26.4 |  | 19.0 |  | 39 | %
Income before income taxes | 178.5 |  | 177.1 |  | 1 | % |  | 358.3 |  | 357.5 |  | — |
Provision for income taxes | 40.0 |  | 39.0 |  | 3 | % |  | 80.0 |  | 79.5 |  | 1 | %
Effective tax rate | 22.4 | % |  | 22.1 | % |  | 30 bps |  | 22.3 | % |  | 22.2 | % |  | 10 bps
Net income attributable to IDEX | $ | 138.6 |  | $ | 138.2 |  | — |  |  | $ | 278.4 |  | $ | 278.2 |  | — |
Diluted earnings per common share attributable to IDEX | $ | 1.82 |  | $ | 1.81 |  | 1 | % |  | $ | 3.66 |  | $ | 3.65 |  | — |

Net Sales
Net sales for the three and six months ended June 30, 2023 increased 6% and 9%, respectively, as compared to the same prior year periods. Organic sales for the same periods increased 3% and 4%, respectively, as a result of price capture across each of our segments, partially offset by the impact of current market conditions on volumes in our Health & Science Technologies businesses. Acquisition-related growth, net of divestitures, was 4% and 6% during the three and six months ended June 30, 2023, respectively, driven by the acquisitions of Iridian in May 2023, Muon Group in November 2022, KZValve in May 2022 and Nexsight in February 2022, net of the divestiture of Knight LLC and its related affiliates (“Knight”) in September 2022. Organic and acquisition-related sales growth were slightly offset by the unfavorable impact of foreign currency translation during both the three and six months ended June 30, 2023.
In the three months ended June 30, 2023, net sales increased 3% domestically and 10% internationally, and sales to customers outside the U.S. were approximately 50% of total sales in the second quarter of 2023 compared with 48% during the same period in 2022. In the six months ended June 30, 2023, net sales increased 6% domestically and 13% internationally, and sales to customers outside the U.S. were approximately 50% of total sales in the first half of 2023 compared with 49% during the same period in 2022.
Cost of Sales
Cost of sales for both the three and six months ended June 30, 2023 increased due to acquisitions, net of divestitures, inflation and higher employee-related costs, partially offset by lower sales volume.
Gross Profit and Gross Margin
Gross profit and Gross margin for both the three and six months ended June 30, 2023 were positively impacted by strong price/cost and favorable operational productivity, partially offset by lower volume leverage, higher employee-related costs and unfavorable mix. While acquisitions, net of divestitures, also positively impacted Gross profit, they resulted in a dilutive impact to overall Gross margin.
32

Table of Contents
Selling, General and Administrative Expenses
Selling, general and administrative expenses in the three months ended June 30, 2023 increased primarily due to the $11.3 million impact from acquisitions, including amortization, net of divestitures. Excluding this impact, selling, general and administrative expenses decreased by $4.5 million, reflecting $3.3 million of lower stock compensation costs due to timing of retirement eligibility of participants, lower variable compensation costs and lower discretionary spending, partially offset by higher employee-related costs as compared with the same period in 2022.
Selling, general and administrative expenses in the six months ended June 30, 2023, increased primarily due to the $28.8 million impact from acquisitions, including amortization, net of divestitures, as well as increases in employee-related costs, which includes an additional $2.7 million of accelerated stock compensation costs for retiree eligible participants, and higher discretionary spending, partially offset by lower variable compensation costs compared with the same period in 2022.
Restructuring Expenses and Asset Impairments
Restructuring expenses and asset impairments increased in both the three and six months ended June 30, 2023 primarily due higher severance costs, which were incurred in conjunction with cost mitigation efforts as a result of the current market environment previously discussed in this section, compared with the same periods in 2022. See Note 12 in the Notes to Condensed Consolidated Financial Statements for further detail.
Other Expense (Income) - Net
Other expense (income) - net increased in both the three and six months ended June 30, 2023 compared with the same periods in 2022. The increase in expense was primarily due to a $7.7 million credit loss reserve on a note receivable from a collaborative partner (See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail). Additionally, the six months ended June 30, 2022 included $2.7 million of gains on the sale of assets that did not reoccur in 2023.
Interest Expense
Interest expense for the three and six months ended June 30, 2023 increased compared to the same period in 2022 due to the borrowings incurred under the Revolving Credit Facility and the Term Facility in connection with the Muon Group acquisition in November 2022.
Income Taxes
The effective tax rates of 22.4% and 22.3% for the three and six months ended June 30, 2023, respectively, were relatively consistent with the effective tax rates of 22.1% and 22.2% during the same periods in 2022.
Results of Reportable Business Segments
The Company has three reportable segments: Fluid & Metering Technologies (“FMT”), Health & Science Technologies (“HST”) and Fire & Safety/Diversified Products (“FSDP”). For a detailed description of the operations within each segment, refer to Note 4 in the Notes to Condensed Consolidated Financial Statements.
Within its three reportable segments, the Company maintains 13 reporting units where the Company focuses on organic growth and strategic acquisitions. Management’s primary measurements of segment performance are sales, adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Adjusted EBITDA margin.

FMT |  | HST |  | FSDP
Pumps |  | Scientific Fluidics & Optics |  | Fire & Safety
Water |  | Sealing Solutions |  | Dispensing
Energy |  | Performance Pneumatic Technologies |  | BAND-IT
Valves |  | Material Processing Technologies |  |
Agriculture |  | Micropump |  |

33

Table of Contents
The table below illustrates the percentages of the share of Net sales and Adjusted EBITDA contributed by each segment on the basis of total segments (not total Company) for the three and six months ended June 30, 2023.

| Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023
| FMT |  | HST |  | FSDP |  | IDEX |  | FMT |  | HST |  | FSDP |  | IDEX
Net sales | 38 | % |  | 40 | % |  | 22 | % |  | 100 | % |  | 38 | % |  | 41 | % |  | 21 | % |  | 100 | %
Adjusted EBITDA(1) | 43 | % |  | 36 | % |  | 21 | % |  | 100 | % |  | 43 | % |  | 37 | % |  | 20 | % |  | 100 | %

(1) Segment Adjusted EBITDA excludes the impact of unallocated corporate costs of $21.6 million and $48.4 million for the three and six months ended June 30, 2023, respectively.
Fluid & Metering Technologies Segment

| Three Months Ended June 30, |  | Components of Change
(Dollars in millions) | 2023 |  | 2022 |  | Change |  | Organic |  | Acq/Div(1) |  | Foreign Currency |  | Total
Net sales | $ | 325.1 |  | $ | 299.9 |  | 8% |  | 10% |  | (1%) |  | (1%) |  | 8%
Adjusted EBITDA | 114.1 |  | 95.0 |  | 20% |  | 20% |  | — |  | — |  | 20%
Adjusted EBITDA margin | 35.1 | % |  | 31.7 | % |  | 340 bps |  | 310 bps |  | 30 bps |  | — |  | 340 bps

| Six Months Ended June 30, |  | Components of Change
(Dollars in millions) | 2023 |  | 2022 |  | Change |  | Organic |  | Acq/Div(1)(2) |  | Foreign Currency |  | Total
Net sales | $ | 646.9 |  | $ | 571.9 |  | 13% |  | 10% |  | 4% |  | (1%) |  | 13%
Adjusted EBITDA | 220.3 |  | 183.4 |  | 20% |  | 17% |  | 4% |  | (1%) |  | 20%
Adjusted EBITDA margin | 34.1 | % |  | 32.1 | % |  | 200 bps |  | 240 bps |  | (30) bps |  | (10) bps |  | 200 bps

(1) Acquisitions included KZValve in May 2022. Divestitures included Knight in September 2022.
(2) Based on the timing of its acquisition, Nexsight results for the first three months of 2023 are reflected in the acquisitions/divestitures column while the remaining year-over-year impact is included in the organic column.
•Net sales in the second quarter of 2023 increased 6% domestically and 11% internationally. Net sales to customers outside the U.S. were approximately 44% of total segment sales in the second quarter of 2023 compared with 43% during the same period in 2022.
•Net sales in the first six months of 2023 increased 12% domestically and 15% internationally. Net sales to customers outside the U.S. were approximately 45% of total segment sales in the first six months of 2023 compared with 44% during the same period in 2022.
•The change in organic net sales for both the three and six months ended June 30, 2023 was attributed to increases in the following:
◦Energy reporting unit driven by operational execution related to improved supply chain conditions and price capture;
◦Water reporting unit driven by price capture, favorability in the municipal water market and operational execution;
◦Pumps reporting unit driven by strong price capture and operational execution, partially offset by softness in the industrial market; and
◦Valves reporting unit driven by strong price capture and demand in Asia.
These increases were partially offset by a decrease in the Agriculture reporting unit driven by distribution inventory recalibration, partially offset by positive OEM demand.
•Adjusted EBITDA margin of 35.1% for the second quarter of 2023 increased 340 basis points compared with 31.7% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦Organic Adjusted EBITDA margin increased 310 basis points due to strong price/cost, higher volume leverage, lower discretionary spending and favorable operational productivity, partially offset by higher employee-related costs and unfavorable mix; and
34

Table of Contents
◦Acquisitions/divestitures positively impacted Adjusted EBITDA margin by 30 basis points due to the accretive impact of acquisitions, net of divestitures, on overall FMT Adjusted EBITDA margin.
•Adjusted EBITDA margin of 34.1% for the first six months of 2023 increased 200 basis points compared with 32.1% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦Organic Adjusted EBITDA margin increased 240 basis points due to strong price/cost, operational productivity and volume leverage, partially offset by higher employee-related costs and unfavorable mix;
◦Acquisitions/divestitures negatively impacted Adjusted EBITDA margin by 30 basis points due to the dilutive impact of acquisitions, net of divestitures, on overall FMT Adjusted EBITDA margin; and
◦Foreign currency negatively impacted Adjusted EBITDA margin by 10 basis points.
Health & Science Technologies Segment

| Three Months Ended June 30, |  | Components of Change
(Dollars in millions) | 2023 |  | 2022 |  | Change |  | Organic |  | Acq/Div(1) |  | Foreign Currency |  | Total
Net sales | $ | 339.5 |  | $ | 326.0 |  | 4% |  | (6%) |  | 10% |  | — |  | 4%
Adjusted EBITDA | 93.7 |  | 103.6 |  | (10%) |  | (19%) |  | 9% |  | — |  | (10%)
Adjusted EBITDA margin | 27.6 | % |  | 31.8 | % |  | (420) bps |  | (420) bps |  | (10) bps |  | 10 bps |  | (420) bps

| Six Months Ended June 30, |  | Components of Change
(Dollars in millions) | 2023 |  | 2022 |  | Change |  | Organic |  | Acq/Div(1) |  | Foreign Currency |  | Total
Net sales | $ | 690.5 |  | $ | 641.2 |  | 8% |  | (2%) |  | 11% |  | (1%) |  | 8%
Adjusted EBITDA | 194.4 |  | 203.4 |  | (4%) |  | (13%) |  | 10% |  | (1%) |  | (4%)
Adjusted EBITDA margin | 28.2 | % |  | 31.7 | % |  | (350) bps |  | (370) bps |  | — |  | 20 bps |  | (350) bps

(1) Acquisitions included Iridian in May 2023 and Muon Group in November 2022.
•Net sales in the second quarter of 2023 decreased 6% domestically and increased 13% internationally. Net sales to customers outside the U.S. were approximately 56% of total segment sales in the second quarter of 2023 compared with 52% during the same period in 2022.
•Net sales in the first six months of 2023 decreased 4% domestically and increased 18% internationally. Net sales to customers outside the U.S. were approximately 57% of total segment sales in the first six months of 2023 compared with 52% during the same period in 2022.
•The change in organic net sales for both the three and six months ended June 30, 2023 was attributed to decreases in the following:
◦Scientific Fluidics & Optics reporting unit driven by lower demand from Analytical Instrumentation and Life Science original equipment manufacturers due to customer inventory recalibration, partially offset by price capture;
◦Sealing Solutions reporting unit driven by softness in the semiconductor market; and
◦Material Processing Technologies reporting unit driven by lower demand in the pharma/biopharma and food/nutrition markets, partially offset by operational execution and price capture.
These decreases were partially offset by an increase in the Performance Pneumatics Technologies reporting unit driven by strong targeted growth performance tied to fuel cells and price capture, partially offset by softness in the industrial market.
•Adjusted EBITDA margin of 27.6% for the second quarter of 2023 decreased 420 basis points compared with 31.8% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦Organic Adjusted EBITDA margin decreased 420 basis points due to unfavorable volume leverage, higher employee-related costs and unfavorable mix, partially offset by strong price/cost as well as lower discretionary spending and lower variable compensation costs;
◦Acquisitions negatively impacted Adjusted EBITDA margin by 10 basis points due to the dilutive impact of acquisitions on overall HST Adjusted EBITDA margin; and
◦Foreign currency positively impacted Adjusted EBITDA margin by 10 basis points.
•Adjusted EBITDA margin of 28.2% for the first six months of 2023 decreased 350 basis points compared with 31.7% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
35

Table of Contents
◦Organic Adjusted EBITDA margin decreased 370 basis points due to unfavorable volume leverage, higher employee-related costs and unfavorable mix, partially offset by strong price/cost; and
◦Foreign currency positively impacted Adjusted EBITDA margin by 20 basis points.
Fire & Safety/Diversified Products Segment

| Three Months Ended June 30, |  | Components of Change
(Dollars in millions) | 2023 |  | 2022 |  | Change |  | Organic |  | Acq/Div |  | Foreign Currency |  | Total
Net sales | $ | 184.8 |  | $ | 171.2 |  | 8% |  | 8% |  | — |  | — |  | 8%
Adjusted EBITDA | 54.5 |  | 45.1 |  | 21% |  | 21% |  | — |  | — |  | 21%
Adjusted EBITDA margin | 29.4 | % |  | 26.4 | % |  | 300 bps |  | 310 bps |  | — |  | (10) bps |  | 300 bps

| Six Months Ended June 30, |  | Components of Change
(Dollars in millions) | 2023 |  | 2022 |  | Change |  | Organic |  | Acq/Div |  | Foreign Currency |  | Total
Net sales | $ | 359.2 |  | $ | 335.9 |  | 7% |  | 9% |  | — |  | (2%) |  | 7%
Adjusted EBITDA | 104.2 |  | 89.5 |  | 16% |  | 18% |  | — |  | (2%) |  | 16%
Adjusted EBITDA margin | 29.0 | % |  | 26.6 | % |  | 240 bps |  | 240 bps |  | — |  | — |  | 240 bps

•Net sales in the second quarter of 2023 increased 14% domestically and 2% internationally. Net sales to customers outside the U.S. were approximately 48% of total segment sales in the second quarter of 2023 compared with 50% during the same period in 2022.
•Net sales in the first six months of 2023 increased 15% domestically and decreased 1% internationally. Net sales to customers outside the U.S. were approximately 48% of total segment sales in the first six months of 2023 compared with 52% during the same period in 2022.
•The change in organic net sales for both the three and six months ended June 30, 2023 was attributed to increases in the following:
◦Fire & Safety reporting unit driven by price capture, share gain with fire original equipment manufacturers, continued demand for rescue tools and operational execution; and
◦BAND-IT reporting unit driven by continued share gain in an otherwise flat automotive market.
In addition, within the Dispensing report unit, timing of North American project sales positively impacted the three and six months ended June 30, 2023 while timing of deliveries within Europe and Asia negatively impacted the three and six months ended June 30, 2023.
•Adjusted EBITDA margin of 29.4% for the second quarter of 2023 increased 300 basis points compared with 26.4% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦Organic Adjusted EBITDA margin increased 310 basis points due to strong price/cost, favorable mix, lower variable compensation costs, higher volume leverage and favorable operational productivity, net of higher employee-related costs; and
◦Foreign currency negatively impacted Adjusted EBITDA margin by 10 basis points.
•Adjusted EBITDA margin of 29.0% for the first six months of 2023 increased 240 basis points compared with 26.6% during the same period in 2022. The change in Adjusted EBITDA margin was attributed to the following:
◦Organic Adjusted EBITDA margin increased 240 basis points due to strong price/cost, higher volume leverage and operational productivity.
36

Table of Contents
Liquidity and Capital Resources
Liquidity
Based on management’s current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Credit Facility will be sufficient to meet its operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, share repurchases and quarterly dividend payments to holders of the Company’s common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings.
Select key liquidity metrics at June 30, 2023 are as follows:

(In millions) |  | June 30, 2023
Working capital |  | $ | 1,001.3 |
Current ratio |  | 3.1 to 1
Cash and cash equivalents |  | $ | 457.0 |
Cash held outside of the United States |  | 377.4 |
Revolving Credit Facility capacity |  | $ | 800.0 |
Borrowings |  | 79.5 |
Letters of credit |  | 7.4 |
Revolving Credit Facility availability |  | $ | 713.1 |

The Company believes that additional borrowings through various financing alternatives remain available, if required.
Operating Working Capital
Operating working capital, calculated as Receivables plus Inventories minus Trade accounts payable, is used by management as a measurement of operational results as well as the short-term liquidity of the Company. The following table details operating working capital as of June 30, 2023 and December 31, 2022:

(In millions) |  | June 30, 2023 |  | December 31, 2022
Receivables |  | $ | 455.2 |  |  | $ | 442.8 |
Inventories |  | 482.5 |  | 470.9
Less: Trade accounts payable |  | 189.7 |  |  | 208.9 |
Operating working capital |  | $ | 748.0 |  |  | $ | 704.8 |

Operating working capital increased $43.2 million to $748.0 million during the six months ended June 30, 2023. Acquisitions and foreign currency translation contributed $18.1 million to the increase in operating working capital. The remaining increase in Operating working capital was primarily driven by Trade accounts payable, which decreased $18.5 million, due to lower purchases in anticipation of decreased volume in the second half of the year. While Inventories increased $1.7 million as compared to the prior year end, inventory reduction efforts in the second quarter of 2023 lowered first quarter elevated levels related to planned production. In addition, Receivables increased $4.9 million as a result of strong price capture.
37

Table of Contents
Cash Flow Summary
The following table is derived from the Condensed Consolidated Statements of Cash Flows:

|  | Six Months Ended June 30,
(In millions) |  | 2023 |  | 2022
Net cash flows provided by (used in): |  |  |  |
Operating activities |  | $ | 289.1 |  |  | $ | 192.0 |
Investing activities |  | (176.6) |  |  | (260.1) |
Financing activities |  | (92.0) |  |  | (197.1) |

Operating Activities
Cash flows provided by operating activities increased $97.1 million to $289.1 million in the six months ended June 30, 2023 primarily due to higher earnings and lower investments in working capital in 2023 as compared with 2022 primarily as a result of efforts to recalibrate inventory levels in response to normalizing market conditions.
Investing Activities
Cash flows used in investing activities decreased $83.5 million to $176.6 million in the six months ended June 30, 2023. The change is primarily due to the purchases of Nexsight and KZValve in 2022, partially offset by the purchase of Iridian, the purchase of marketable securities and higher capital expenditures in 2023.
Financing Activities
Cash flows used in financing activities decreased $105.1 million to $92.0 million in the six months ended June 30, 2023 from $197.1 million in the prior year period. The decrease was primarily the result of lower repurchases of common stock, which were $109.4 million higher during the prior year period.
Free Cash Flow
The Company believes free cash flow, a non-GAAP measure, is an important measure of performance because it provides a measurement of cash generated from operations that is available for payment obligations such as operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company’s common stock as well as for funding acquisitions and share repurchases. Free cash flow is calculated as cash flows provided by operating activities less capital expenditures.
The following table reconciles free cash flow to cash flows provided by operating activities:

|  | Six Months Ended June 30,
(Dollars in millions) |  | 2023 |  | 2022
Cash flows provided by operating activities |  | $ | 289.1 |  |  | $ | 192.0 |
Less: capital expenditures |  | 48.2 |  |  | 31.7 |
Free cash flow |  | $ | 240.9 |  |  | $ | 160.3 |
Free cash flow as a percent of adjusted net income attributable to IDEX |  | 74.4 | % |  | 52.8 | %

The increase in free cash flow as compared to 2022 is due to lower investments in working capital discussed above in 2023 as compared with 2022, partially offset by higher capital expenditures.
38

Table of Contents
Cash Requirements
Capital Expenditures
Capital expenditures generally include machinery and equipment that support growth and improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures. Cash flows from operations were more than adequate to fund capital expenditures of $48.2 million and $31.7 million in the first six months of 2023 and 2022, respectively.
Share Repurchases
During the six months ended June 30, 2023, the Company repurchased 5,400 shares at a cost of $1.1 million, of which $0.1 million did not settle until July 2023. As of June 30, 2023, the amount of share repurchase authorization remaining was $562.8 million. For additional information regarding the Company’s share repurchase program, refer to Note 14 in the Notes to Condensed Consolidated Financial Statements.
Dividends
Total dividend payments to common shareholders were $93.9 million during the six months ended June 30, 2023 compared with $86.9 million during the six months ended June 30, 2022.
Covenants
The key financial covenants that the Company is required to maintain in connection with the Revolving Credit Facility, the Term Facility, the 3.37% Senior Notes and the 5.13% Senior Notes, are a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1. At June 30, 2023, the Company was in compliance with these financial covenants, as the Company’s interest coverage ratio was 21.03 to 1 for covenant calculation purposes and the leverage ratio was 1.52 to 1. There are no financial covenants relating to the 2.625% Senior Notes or the 3.00% Senior Notes; however, both are subject to cross-default provisions.
Credit Ratings
The Company’s credit ratings, which were independently developed by the following credit agencies, are detailed below:
•S&P Global Ratings affirmed the Company’s corporate credit rating of BBB (stable outlook) in August 2022.
•Moody’s Investors Service affirmed the Company’s corporate credit rating of Baa2 (stable outlook) in December 2021.
•Fitch Ratings reaffirmed the Company’s corporate credit rating of BBB+ (stable outlook) in April 2023.
Critical Accounting Estimates
As discussed in the Annual Report on Form 10-K for the year ended December 31, 2022, the preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. There have been no changes to the Company’s critical accounting estimates described in the Annual Report on Form 10-K for the year ended December 31, 2022.
39

Table of Contents
Non-GAAP Disclosures
Set forth below are reconciliations of each of Organic net sales, Adjusted gross profit, Adjusted gross margin, Adjusted net income attributable to IDEX, Adjusted diluted earnings per share (“EPS”) attributable to IDEX, Consolidated Adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”) and Consolidated Adjusted EBITDA margin to its respective most directly comparable U.S. GAAP measure. Management uses these metrics to measure performance of the Company since they exclude items that are not reflective of ongoing operations, as identified in the reconciliations below. Management also supplements its U.S. GAAP financial statements with adjusted information to provide investors with greater insight, transparency and a more comprehensive understanding of the information used by management in its financial and operational decision making.
This report references organic sales, a non-GAAP measure, that excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping to identify underlying growth trends in the Company’s business and facilitating easier comparisons of the Company’s revenue with prior and future periods and to its peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long-term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers.
Management believes that Adjusted EBITDA, which is EBITDA adjusted for items that are not reflective of ongoing operations, is useful as a performance indicator of ongoing operations. The Company believes that Adjusted EBITDA is useful to investors as an indicator of the strength and performance of the Company and its segments’ ongoing business operations and a way to evaluate and compare operating performance and value companies within the Company’s industry. Management believes that Adjusted EBITDA margin is useful for the same reason as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies.
This report also references free cash flow. This non-GAAP measure is discussed and reconciled to its most directly comparable U.S. GAAP measure in the section above titled “Free Cash Flow.”
The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

1. Reconciliations of the Change in Net Sales to Organic Net Sales |  |  |  |  |  |  |
| Three Months Ended June 30, 2023
| FMT |  | HST |  | FSDP |  | IDEX
Change in net sales | 8 | % |  | 4 | % |  | 8 | % |  | 6 | %
- Net impact from acquisitions/divestitures | (1 | %) |  | 10 | % |  | — |  |  | 4 | %
- Impact from foreign currency | (1 | %) |  | — |  |  | — |  |  | (1 | %)
Change in organic net sales | 10 | % |  | (6 | %) |  | 8 | % |  | 3 | %

| Six Months Ended June 30, 2023
| FMT |  | HST |  | FSDP |  | IDEX
Change in net sales | 13 | % |  | 8 | % |  | 7 | % |  | 9 | %
- Net impact from acquisitions/divestitures | 4 | % |  | 11 | % |  | — |  |  | 6 | %
- Impact from foreign currency | (1 | %) |  | (1 | %) |  | (2 | %) |  | (1 | %)
Change in organic net sales | 10 | % |  | (2 | %) |  | 9 | % |  | 4 | %

40

Table of Contents

2. Reconciliations of Reported-to-Adjusted Gross Profit and Margin (dollars in millions)
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Gross profit | $ | 378.0 |  | $ | 356.9 |  | $ | 760.5 |  | $ | 699.4
+ Fair value inventory step-up charges | — |  | 0.4 |  | — |  | 0.4
Adjusted gross profit | $ | 378.0 |  | $ | 357.3 |  | $ | 760.5 |  | $ | 699.8
Net sales | $ | 846.2 |  | $ | 796.1 |  | $ | 1,691.6 |  | $ | 1,547.2
Gross margin | 44.7 | % |  | 44.8 | % |  | 45.0 | % |  | 45.2 | %
Adjusted gross margin | 44.7 | % |  | 44.9 | % |  | 45.0 | % |  | 45.2 | %

3. Reconciliations of Reported-to-Adjusted Net Income and Diluted EPS (in millions, except per share amounts)
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Reported net income attributable to IDEX | $ | 138.6 |  |  | $ | 138.2 |  |  | $ | 278.4 |  |  | $ | 278.2 |
+ Restructuring expenses and asset impairments | 3.6 |  |  | 2.8 |  |  | 4.1 |  |  | 2.8 |
+ Tax impact on restructuring expenses and asset impairments | (0.8) |  |  | (0.7) |  |  | (0.9) |  |  | (0.7) |
+ Fair value inventory step-up charges | — |  |  | 0.4 |  |  | — |  |  | 0.4 |
+ Tax impact on fair value inventory step-up charges | — |  |  | (0.1) |  |  | — |  |  | (0.1) |
- Gains on sales of assets | — |  |  | — |  |  | — |  |  | (2.7) |
+ Tax impact on gains on sales of assets | — |  |  | — |  |  | — |  |  | 0.6 |
+ Credit loss on note receivable from collaborative partner(1) | 7.7 |  |  | — |  |  | 7.7 |  |  | — |
+ Tax impact on credit loss on note receivable from collaborative partner | (1.6) |  |  | — |  |  | (1.6) |  |  | — |
+ Acquisition-related intangible asset amortization | 23.2 |  |  | 16.9 |  |  | 46.8 |  |  | 32.2 |
+ Tax impact on acquisition-related intangible asset amortization | (5.3) |  |  | (3.9) |  |  | (10.5) |  |  | (7.3) |
Adjusted net income attributable to IDEX | $ | 165.4 |  |  | $ | 153.6 |  |  | $ | 324.0 |  |  | $ | 303.4 |

(1) Represents a reserve on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.
41

Table of Contents

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Reported diluted EPS attributable to IDEX | $ | 1.82 |  |  | $ | 1.81 |  |  | $ | 3.66 |  |  | $ | 3.65 |
+ Restructuring expenses and asset impairments | 0.05 |  |  | 0.04 |  |  | 0.06 |  |  | 0.04 |
+ Tax impact on restructuring expenses and asset impairments | (0.01) |  |  | (0.01) |  |  | (0.01) |  |  | (0.01) |
+ Fair value inventory step-up charges | — |  |  | — |  |  | — |  |  | — |
+ Tax impact on fair value inventory step-up charges | — |  |  | — |  |  | — |  |  | — |
- Gains on sales of assets | — |  |  | — |  |  | — |  |  | (0.03) |
+ Tax impact on gains on sales of assets | — |  |  | — |  |  | — |  |  | 0.01 |
+ Credit loss on note receivable from collaborative partner(1) | 0.10 |  |  | — |  |  | 0.10 |  |  | — |
+ Tax impact on credit loss on note receivable from collaborative partner | (0.02) |  |  | — |  |  | (0.02) |  |  | — |
+ Acquisition-related intangible asset amortization | 0.31 |  |  | 0.22 |  |  | 0.62 |  |  | 0.42 |
+ Tax impact on acquisition-related intangible asset amortization | (0.07) |  |  | (0.04) |  |  | (0.14) |  |  | (0.10) |
Adjusted diluted EPS attributable to IDEX | $ | 2.18 |  |  | $ | 2.02 |  |  | $ | 4.27 |  |  | $ | 3.98 |
Diluted weighted average shares outstanding | 75.9 |  |  | 76.1 |  |  | 75.9 |  |  | 76.2 |

(1) Represents a reserve on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.

4. Reconciliations of Net Income to Adjusted EBITDA (dollars in millions)
| Three Months Ended June 30,
| 2023 |  | 2022
| FMT |  | HST |  | FSDP |  | Corporate |  | IDEX |  | FMT |  | HST |  | FSDP |  | Corporate |  | IDEX
Reported net income | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | 138.5 |  | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | 138.1
+ Provision for income taxes | — |  | — |  | — |  | — |  | 40.0 |  | — |  | — |  | — |  | — |  | 39.0
+ Interest expense | — |  | — |  | — |  | — |  | 13.3 |  | — |  | — |  | — |  | — |  | 9.5
- Other income (expense) - net | — |  | — |  | — |  | — |  | (8.3) |  | — |  | — |  | — |  | — |  | —
Operating income (loss) | 103.3 |  | 67.5 |  | 50.6 |  | (21.3) |  | 200.1 |  | 82.9 | — | 86.5 |  | 39.9 |  | (22.7) |  | 186.6
+ Other income (expense) - net | 0.4 |  | (0.2) |  | (0.3) |  | (8.2) |  | (8.3) |  | 0.2 |  | 1.2 |  | 0.5 |  | (1.9) |  | —
+ Depreciation | 4.1 |  | 7.8 |  | 2.3 |  | 0.2 |  | 14.4 |  | 4.2 |  | 6.1 |  | 2.1 |  | 0.1 |  | 12.5
+ Amortization | 5.7 |  | 15.9 |  | 1.6 |  | — |  | 23.2 |  | 5.6 |  | 9.7 |  | 1.6 |  | — |  | 16.9
+ Fair value inventory step-up charges | — |  | — |  | — |  | — |  | — |  | 0.4 |  | — |  | — |  | — |  | 0.4
+ Restructuring expenses and asset impairments | 0.6 |  | 2.7 |  | 0.3 |  | — |  | 3.6 |  | 1.7 |  | 0.1 |  | 1.0 |  | — |  | 2.8
+ Credit loss on note receivable from collaborative partner(1) | — |  | — |  | — |  | 7.7 |  | 7.7 |  | — |  | — |  | — |  | — |  | —
Adjusted EBITDA | $ | 114.1 |  | $ | 93.7 |  | $ | 54.5 |  | $ | (21.6) |  | $ | 240.7 |  | $ | 95.0 |  | $ | 103.6 |  | $ | 45.1 |  | $ | (24.5) |  | $ | 219.2
Net sales (eliminations) | $ | 325.1 |  | $ | 339.5 |  | $ | 184.8 |  | $ | (3.2) |  | $ | 846.2 |  | $ | 299.9 |  | $ | 326.0 |  | $ | 171.2 |  | $ | (1.0) |  | $ | 796.1
Net income margin |  |  |  |  |  |  |  |  | 16.4 | % |  |  |  |  |  |  |  |  |  | 17.3 | %
Adjusted EBITDA margin | 35.1 | % |  | 27.6 | % |  | 29.4 | % |  | n/m |  | 28.4 | % |  | 31.7 | % |  | 31.8 | % |  | 26.4 | % |  | n/m |  | 27.5 | %

(1) Represents a reserve on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.
42

Table of Contents

| Six Months Ended June 30,
| 2023 |  | 2022
| FMT |  | HST |  | FSDP |  | Corporate |  | IDEX |  | FMT |  | HST |  | FSDP |  | Corporate |  | IDEX
Reported net income | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | 278.3 |  | $ | — |  | $ | — |  | $ | — |  | $ | — |  | $ | 278.0
+ Provision for income taxes | — |  | — |  | — |  | — |  | 80.0 |  | — |  | — |  | — |  | — |  | 79.5
+ Interest expense | — |  | — |  | — |  | — |  | 26.4 |  | — |  | — |  | — |  | — |  | 19.0
- Other income (expense) - net | — |  | — |  | — |  | — |  | (7.7) |  | — |  | — |  | — |  | — |  | 2.3
Operating income (loss) | 199.8 |  | 145.0 |  | 96.6 |  | (49.0) |  | 392.4 |  | 163.3 |  | 170.1 |  | 80.4 |  | (39.6) |  | 374.2
+ Other income (expense) - net | 0.9 |  | (0.5) |  | (0.5) |  | (7.6) |  | (7.7) |  | 1.8 |  | 1.4 |  | 2.1 |  | (3.0) |  | 2.3
+ Depreciation | 7.2 |  | 15.1 |  | 4.4 |  | 0.5 |  | 27.2 |  | 8.1 |  | 12.2 |  | 4.2 |  | 0.2 |  | 24.7
+ Amortization | 11.7 |  | 31.8 |  | 3.3 |  | — |  | 46.8 |  | 9.3 |  | 19.6 |  | 3.3 |  | — |  | 32.2
+ Fair value inventory step-up charges | — |  | — |  | — |  | — |  | — |  | 0.4 |  | — |  | — |  | — |  | 0.4
+ Restructuring expenses and asset impairments | 0.7 |  | 3.0 |  | 0.4 |  | — |  | 4.1 |  | 1.7 |  | 0.1 |  | 1.0 |  | — |  | 2.8
- Gains on sales of assets | — |  | — |  | — |  | — |  | — |  | (1.2) |  | — |  | (1.5) |  | — |  | (2.7)
+ Credit loss on note receivable from collaborative partner(1) | — |  | — |  | — |  | 7.7 |  | 7.7 |  | — |  | — |  | — |  | — |  | —
Adjusted EBITDA | $ | 220.3 |  | $ | 194.4 |  | $ | 104.2 |  | $ | (48.4) |  | $ | 470.5 |  | $ | 183.4 |  | $ | 203.4 |  | $ | 89.5 |  | $ | (42.4) |  | $ | 433.9
Net sales (eliminations) | $ | 646.9 |  | $ | 690.5 |  | $ | 359.2 |  | $ | (5.0) |  | $ | 1,691.6 |  | $ | 571.9 |  | $ | 641.2 |  | $ | 335.9 |  | $ | (1.8) |  | $ | 1,547.2
Net income margin |  |  |  |  |  |  |  |  | 16.4 | % |  |  |  |  |  |  |  |  |  | 18.0 | %
Adjusted EBITDA margin | 34.1 | % |  | 28.2 | % |  | 29.0 | % |  | n/m |  | 27.8 | % |  | 32.1 | % |  | 31.7 | % |  | 26.6 | % |  | n/m |  | 28.0 | %

(1) Represents a reserve on an investment with a collaborative partner that may no longer be recoverable. See Note 3 in the Notes to Condensed Consolidated Financial Statements for further detail.
43

Table of Contents
Cautionary Statement Under the Private Securities Litigation Reform Act
This quarterly report on Form 10-Q, including the “Overview,” “Results of Operations” and “Liquidity and Capital Resources” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, anticipated changes in the second half of 2023, anticipated future acquisition behavior, availability of cash and financing alternatives and the anticipated benefits of the Company’s recent acquisitions, including the acquisitions of Nexsight, KZValve, Muon Group and Iridian, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “guidance,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report.
The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets and adverse developments affecting the financial services industry; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company’s results; the impact of health epidemics and pandemics and terrorist attacks and wars, which could have an adverse impact on the Company's business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters.
Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.
44

Table of Contents
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes with respect to market risks disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
Item 4. Controls and Procedures
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2023.
There has been no change in the Company’s internal control over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
45

Table of Contents
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The Company and its subsidiaries are party to legal proceedings arising in the ordinary course of business as described in Note 1 7 in Part I, Item 1, “Legal Proceedings,” and such disclosure is incorporated by reference into this Item 1, “Legal Proceedings.”
The Company’s threshold for disclosing material environmental legal proceedings involving a government authority where potential monetary sanctions are involved is $1.0 million.
In addition, the Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Asbestos-related claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims have been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.
Item 1A. Risk Factors
There have been no material changes with respect to risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about the Company’s purchases of its common stock during the quarter ended June 30, 2023:

Period | Total Number of Shares Purchased |  | Average Price Paid per Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate Dollar Value that May Yet be Purchased Under the Plans or Programs(1)
April 1, 2023 to April 30, 2023 | 1,400 |  |  | $ | 199.60 |  |  | 1,400 |  |  | $ | 563,561,945 |
May 1, 2023 to May 31, 2023 | 2,900 |  |  | 198.86 |  |  | 2,900 |  |  | 562,982,346 |
June 1, 2023 to June 30, 2023 | 1,100 |  |  | 198.79 |  |  | 1,100 |  |  | 562,763,657 |
Total | 5,400 |  |  | $ | 199.59 |  |  | 5,400 |  |  | $ | 562,763,657 |

(1)On March 17, 2020, the Company’s Board of Directors approved an increase of $500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorization of the Board of Directors of $300.0 million on December 1, 2015. These authorizations have no expiration date.
Item 5. Other Information
During the quarter ended June 30, 2023, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
46

Table of Contents
Item 6. Exhibits

Exhibit Number |  | Description
10.1**, * |  | IDEX Management Incentive Compensation Plan, as Amended and Restated on June 21, 2023
31.1* |  | Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002
31.2* |  | Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002
32.1* |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2* |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350
101* |  | The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 formatted in Inline eXtensible Business Reporting Language (iXBRL) includes: (i) the Cover Page, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Income, (iv) the Condensed Consolidated Statements of Comprehensive Income, (v) the Condensed Consolidated Statements of Equity, (vi) the Condensed Consolidated Statements of Cash Flows, and (vii) Notes to the Condensed Consolidated Financial Statements.
104* |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** Management contract or compensatory plan or agreement.

47

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| IDEX Corporation
| By: | /s/ WILLIAM K. GROGAN
|  | William K. Grogan
|  | Senior Vice President and Chief Financial Officer (Principal Financial Officer)
| By: | /s/ ALLISON S. LAUSAS
|  | Allison S. Lausas
|  | Vice President and Chief Accounting Officer (Principal Accounting Officer)

Date: July 27, 2023
48